0001213900-16-016025.txt : 20160815 0001213900-16-016025.hdr.sgml : 20160815 20160815161510 ACCESSION NUMBER: 0001213900-16-016025 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 48 CONFORMED PERIOD OF REPORT: 20160630 FILED AS OF DATE: 20160815 DATE AS OF CHANGE: 20160815 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Immudyne, Inc. CENTRAL INDEX KEY: 0000948320 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] IRS NUMBER: 760238453 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 333-184487 FILM NUMBER: 161832892 BUSINESS ADDRESS: STREET 1: 50 SPRING MEADOW ROAD CITY: MT. KISCO STATE: NY ZIP: 10549 BUSINESS PHONE: (914) 244-1777 MAIL ADDRESS: STREET 1: 50 SPRING MEADOW ROAD CITY: MT. KISCO STATE: NY ZIP: 10549 FORMER COMPANY: FORMER CONFORMED NAME: IMMUDYNE INC DATE OF NAME CHANGE: 19950720 10-Q 1 f10q0616_immudyne.htm QUARTERLY REPORT

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2016

OR

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission file number: 333-184487

IMMUDYNE, INC.

(Exact name of registrant as specified in its charter)

Delaware		76-0238453
(State or other jurisdiction of		(IRS Employer
incorporation or organization)		Identification No.)

50 Spring Meadow Rd.
Mount Kisco, NY		10549
(Address of principal executive offices)		(Zip Code)

(914) 244-1777

(Registrant’s telephone number, including area code)

Indicate by checkmark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the last 90 days.

YES ☒ NO ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

YES ☒ NO ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer, “accelerated filer,” “non-accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☐	Smaller reporting company	☒
(do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

YES ☐ NO ☒

34,310,375 shares of common stock outstanding as of August 15, 2016.

Immudyne, Inc.

Table of Contents

		Page
Note about Forward-Looking Statements		i

PART I. FINANCIAL INFORMATION

Item 1.	Financial Statements	1
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	17
Item 3.	Quantitative and Qualitative Disclosures about Market Risk	22
Item 4.	Controls and Procedures	22

PART II. OTHER INFORMATION

Item 1.	Legal Proceedings	23
Item 1A.	Risk Factors	23
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	23
Item 3.	Defaults Upon Senior Securities	23
Item 4.	Mine Safety Disclosures	23
Item 5.	Other Information	23
Item 6.	Exhibits	23

Signatures		24

Exhibit Index		25

NOTE ABOUT FORWARD-LOOKING STATEMENTS

This report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”) regarding our company that include, but are not limited to, projections of earnings, revenue or other financial items; statements of the plans, strategies and objectives of management for future operations; statements concerning proposed new products, services or developments; statements regarding future economic conditions or performance; statements of belief; and statements of assumptions underlying any of the foregoing. These forward-looking statements are based on our current expectations, estimates and projections about our industry, management’s beliefs and certain assumptions made by us. Words such as “anticipates,” “expects,” “intends,” “plans,” “predicts,” “potential,” “believes,” “seeks,” “hopes,” “estimates,” “should,” “may,” “will,” “with a view to” and variations of these words or similar expressions are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Although we believe that our expectations expressed in these forward-looking statements are reasonable, our expectations may later be found to be incorrect. Our actual results could be materially different from our expectations. Important risks and factors that could cause our actual results to be materially different from our expectations are set forth in “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” “Our Business” and other sections in this report. Other sections of this report include additional factors that could adversely impact our business and financial performance.

Unless otherwise indicated, information in this report concerning economic conditions and our industry is based on information from independent industry analysts and publications, as well as our estimates. Except where otherwise noted, our estimates are derived from publicly available information released by third party sources, as well as data from our internal research, and are based on such data and our knowledge of our industry, which we believe to be reasonable. Unless otherwise indicated, none of the independent industry publication market data cited in this report was prepared on our or our affiliates’ behalf.

The forward-looking statements made in this report are based only on events or information as of the date on which the statements are made in this report. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this report and the documents we refer to in this report and have filed as exhibits to this report completely and with the understanding that our actual future results may be materially different from what we expect.

Additional information on the various risks and uncertainties potentially affecting our operating results are discussed in this report and other documents we file with the Securities and Exchange Commission (the “SEC”). We undertake no obligation to revise or update publicly any forward-looking statements for any reason, except as required by law. Given these risks and uncertainties, readers are cautioned not to place undue reliance on these forward-looking statements.

As used in this report, “Immudyne,” “Company,” “we,” “our” and similar terms refer to Immudyne Inc., unless the context indicates otherwise.

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

Immudyne, Inc.

Consolidated Balance Sheets

	June 30, 2016			December 31, 2015
	(unaudited)
ASSETS

Current Assets
Cash	$	235,452		$	232,984
Trade accounts receivable, net		451,074			154,436
Inventory, net		179,255			61,051
Total Current Assets		865,781			448,471

LIABILITIES AND STOCKHOLDERS' EQUITY

Current Liabilities
Accounts payable and accrued expenses	$	421,640		$	167,481
Notes payable		100,000			100,000
Total Current Liabilities		521,640			267,481

Immudyne, Inc. Stockholders’ equity
Common stock, $0.01 par value; 50,000,000 shares authorized, 34,310,375 and 32,010,375 shares issued and outstanding as of June 30, 2016 and December 31, 2015, respectively		343,103			320,103
Additional paid-in capital		8,783,487			8,366,313
Accumulated (deficit)		(8,848,363	)		(8,586,338	)

Total Immudyne, Inc. Stockholders’ Equity		278,227			100,078

Non-controlling interest		65,914			80,912

Total Stockholders’ Equity		344,141			180,990

Total Liabilities and Stockholders’ Equity	$	865,781		$	448,471

The accompanying notes are an integral part of these consolidated financial statements

Immudyne, Inc.

Consolidated Statements of Operations
(unaudited)

	Three Months Ended June 30,						Six Months Ended June 30,
	2016			2015			2016			2015

Net sales	$	1,227,247		$	277,353		$	2,868,275		$	565,630

Cost of sales		700,977			89,503			2,038,919			163,719

Gross Profit		526,270			187,850			829,356			401,911

Operating expenses
Compensation and related expenses		475,056			114,774			715,511			200,164
Professional fees		125,359			26,314			194,674			61,822
General and administrative expenses		79,487			63,932			177,899			149,261
Total operating expenses		679,902			205,020			1,088,084			411,247

Operating (Loss)		(153,632	)		(17,170	)		(258,728	)		(9,336	)

Interest (expense)		(2,750	)		(8,158	)		(5,813	)		(18,626	)

Net (Loss) Before Taxes		(156,382	)		(25,328	)		(264,541	)		(27,962	)
Deferred income tax benefit		-			4,300			-			8,600

Net (Loss)		(156,382	)		(21,028	)		(264,541	)		(19,362	)

Net income (Loss) attributable to noncontrolling interests		43,594			-			(2,516	)		-

Net (Loss) attributable to Immudyne, Inc.	$	(199,976	)	$	(21,028	)	$	(262,025	)	$	(19,362	)

Basic and diluted (loss) per share attributable to Immudyne, Inc.	$	(0.01	)	$	(0.00	)	$	(0.01	)	$	(0.00	)

Average number of common shares outstanding
Basic		32,338,946			30,650,000			32,174,661			30,204,973
Diluted		32,338,946			30,650,000			32,174,661			30,204,973

The accompanying notes are an integral part of these consolidated financial statements

Immudyne, Inc.

Consolidated Statement of Stockholders’ Equity
For the six months ended June 30, 2016
(unaudited)

	Immudyne, Inc.
	Common Stock				Additional Paid-in		Accumulated			Sub			Noncontrolling
	Shares		Amount		Capital		(Deficit)			Total			interest			Total

Balance at December 31, 2015		32,010,375	$	320,103	$	8,366,313	$	(8,586,338	)	$	100,078		$	80,912		$	180,990

Amortization of stock options		-		-		77,733		-			77,733			-			77,733

Issuance of common stock for services		2,300,000		23,000		207,000		-			230,000			-			230,000

Reduction in noncontrolling interest		-		-		91,612		-			91,612			(91,612	)		-

Issuance of stock options		-		-		40,829		-			40,829			-			40,829

Investment in subsidiary by noncontrolling interest		-		-		-		-			-			79,130			79,130

Net (loss)		-		-		-		(262,025	)		(262,025	)		(2,516	)		(264,541	)

Balance at June 30, 2016		34,310,375	$	343,103	$	8,783,487	$	(8,848,363	)	$	278,227		$	65,914		$	344,141

The accompanying notes are an integral part of these consolidated financial statements

Immudyne, Inc.

Consolidated Statements of Cash Flows
(unaudited)

	Six Months Ended June 30,
	2016			2015

CASH FLOWS FROM OPERATING ACTIVITIES
Net (Loss)	$	(264,541	)	$	(19,362	)
Adjustments to reconcile net (loss) to net cash (used) by operating activities
Depreciation		-			28,487
Deferred tax benefit		-			(8,600	)
Stock compensation expense		118,562			4,000
Issuance of common stock for services		230,000			-
Changes in Assets And Liabilities
Trade accounts receivable		(296,638	)		(120,355	)
Inventory		(118,204	)		19,529
Accounts payable and accrued expenses		254,159			39,868
Net cash (used) by operating activities		(76,662	)		(56,433	)

CASH FLOWS FROM FINANCING ACTIVITIES
Investment in subsidiary by noncontrolling interest		79,130			-
Increase in notes payable		-			130,000
Repayment of notes payable		-			(58,714	)
Purchase of Company stock		-			(10,800	)
Net cash provided by financing activities		79,130			60,486

Net increase in cash		2,468			4,053

Cash at beginning of the period		232,984			75,495

Cash at end of the period	$	235,452		$	79,548

Supplemental Disclosure of Cash Flow Information
Cash paid during the period for interest	$	5,813		$	18,626

The accompanying notes are an integral part of these consolidated financial statements

Immudyne, Inc.

Notes to Consolidated Financial Statements

June 30, 2016

(unaudited)

1.	Organization and Going Concern

Immudyne, Inc. (the “Company”) is a Delaware corporation established to develop, manufacture and sell natural immune support products containing the Company’s proprietary yeast beta glucans, a group of beta glucans naturally occurring in the cell walls of yeast that have been shown through testing and analysis to support the immune system. The Company’s products include once a day oral intake tablets and topical creams and gels for skin application. The Company concentrates its sales and marketing efforts on healthcare professionals, distributors for its all-natural raw material ingredient products and direct-to-consumer sales.

In 2015, the Company formed a joint venture domiciled in Puerto Rico, Innate Skincare, LLC d/b/a Innate Scientific, LLC (“Innate”). Under the terms of the joint venture agreement, the Company held a 33.3% equity interest, and a 51% controlling voting interest, in Innate. On January 20, 2016, Innate amended its limited liability company operating agreement and changed its legal name to Immudyne PR LLC (“Immudyne PR”). On April 1, 2016, Immudyne PR further amended its operating agreement and restated the Company’s ownership and voting interest in Immudyne PR increased to 78.16667%. Immudyne PR was formed to launch a complete skin care regime formulated using strategic ingredients provided by the Company. Immudyne PR is also currently pursuing other opportunities.

The Company has funded operations in the past through the sales of its products, issuance of common stock and through loans and advances from officers and directors. The Company’s continued operations are dependent upon obtaining an increase in its sales volume and the continued financial support from officers and directors or the issuance of additional shares of common stock.

The accompanying financial statements have been prepared on the basis that the Company will continue as a going concern, which assumes the realization of assets and the satisfaction of liabilities in the normal course of business. At June 30, 2016, the Company has an accumulated deficit approximating $8.8 million and has incurred negative cash flows from operations. These conditions raise substantial doubt about the Company's ability to continue as a going concern. The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Based on the Company's cash balance at June 30, 2016, and projected cash needs for the remainder of 2016, management estimates that it will need to increase sales revenue and/or raise additional capital to cover operating and capital requirements for the 2016 year. Management plans on raising the additional needed funds through increased sales volume, issuing additional shares of common stock or other equity securities, or obtaining debt financing. Although management has been successful to date in raising necessary funding, there can be no assurance that sales revenue will substantially increase or that any required future financing can be successfully completed on a timely basis, or on terms acceptable to the Company.

Immudyne, Inc.

Notes to Consolidated Financial Statements

June 30, 2016

(unaudited)

2.	Summary of Significant Accounting Policies

Unaudited Financial Statements

The accompanying unaudited financial statements have been prepared in accordance with generally accepted accounting principles for financial information and with the instructions to Form 10-Q. They do not include all information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. The unaudited financial statements should be read in conjunction with those financial statements included in the Company’s previously filed Form 10-K for the year ended December 31, 2015. In the opinion of management, all adjustments considered necessary for a fair presentation, consisting solely of normal recurring adjustments, have been made. Operating results for the six months ended June 30, 2016 are not necessarily indicative of the results that may be expected for the year ending December 31, 2016.

Basis of Presentation and Use of Estimates

The consolidated financial statements include the accounts of the Company and its controlled subsidiary, Immudyne PR. The non- controlling interest in Immudyne PR represents the 21.833% equity interest held by other members of the joint venture. All intercompany transactions have been eliminated.

The Company prepares its consolidated financial statements in conformity with accounting principles generally accepted in the United States of America which requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Some of the more significant estimates required to be made by management include the valuation of inventory and stockholders’ equity based transactions. Actual results could differ from those estimates.

Inventory

At June 30, 2016 and December 31, 2015, inventory consisted primarily of cosmetic and nutraceutical additives, and finished cosmetic products. Inventory is maintained in the Company’s leased Kentucky warehouse and third party warehouses in Nevada and Louisiana.

Immudyne, Inc.

Notes to Consolidated Financial Statements

June 30, 2016

(unaudited)

2.	Summary of Significant Accounting Policies (continued)

Inventory (continued)

Inventory is valued at the lower of cost or market with cost determined on a first-in, first-out (“FIFO”) basis. Management compares the cost of inventory with the net realizable value and an allowance is made for writing down inventory to market value, if lower. At June 30, 2016 and December 31, 2015 the Company recorded an inventory reserve in the amount of $20,000. Inventory consists of the following:

	June 30, 2016		December 31, 2015

Raw materials	$	56,957	$	25,761
Finished products		122,298		35,290
	$	179,255	$	61,051

Revenue Recognition

The Company’s policy is to record revenue as earned when a firm commitment, indicating sales quantity and price exists, delivery has taken place and collectability is reasonably assured. The Company generally records sales of nutraceutical and cosmetic additives once the product is shipped to the customer, and for sales of finished cosmetic products once the customer places the order and the product is simultaneously shipped. Provisions for discounts, returns, allowances, customer rebates and other adjustments are netted with gross sales. The Company accounts for such provisions during the same period in which the related revenues are earned. Customer discounts, returns and rebates approximated $620,000 and $1,050,000 in the three-month and six-month periods ended June 30, 2016, respectively. Customer discounts, returns and rebates were not significant in the three-month and six-month periods ended June 30, 2015.

Delivery is considered to have occurred when title and risk of loss have transferred to the customer. If title does not pass until the product reaches the customer’s delivery site or the customer accepts the product, then recognition of revenue is deferred until that time. There are no formal sales incentives offered to any of the Company’s customers. Volume discounts may be offered from time to time to customers purchasing large quantities on a per transaction basis.

Revenue for the six-month period ended June 30, 2016 consisted of nutraceutical and cosmetic additives ($528,220) and finished cosmetic products ($2,340,055). Revenue for the six month period ended June 30, 2015 consisted solely of nutraceutical and cosmetic additives. Revenue for the three-month period ended June 30, 2016 consisted of nutraceutical and cosmetic additives ($262,310) and finished cosmetic products ($964,937). Revenue for the three month period ended June 30, 2015 consisted solely of nutraceutical and cosmetic additives.

Accounts receivable

Accounts receivable are carried at original invoice amount less an estimate made for holdbacks and doubtful receivables based on a review of all outstanding amounts. Management determines the allowance for doubtful accounts by regularly evaluating individual customer receivables and considering a customer’s financial condition, credit history and current economic conditions and sets up an allowance for doubtful accounts when collection is uncertain. Customers’ accounts are written off when all attempts to collect have been exhausted. Recoveries of accounts receivable previously written off are recorded as income when received. At June 30, 2016 and December 31, 2015 the accounts receivable reserve was approximately $87,000 and $18,000, respectively.

Immudyne, Inc.

Notes to Consolidated Financial Statements

June 30, 2016

(unaudited)

2.	Summary of Significant Accounting Policies (continued)

Segments

The guidance for disclosures about segments of an enterprise requires that a public business enterprise report financial and descriptive information about its operating segments. Generally, financial information is required to be reported on the basis used internally for evaluating segment performance and resource allocation. The Company manages its operations in two reportable segments for purposes of assessing performance and making operating decisions. Revenue is generated predominately in the United States, and all significant assets are held in the United States, or United States territories.

A summary of the company’s reportable segments is as follows:

Total assets:

	June 30, 2016			December 31, 2015
Nutraceutical and Cosmetic Additives	$	417,818		$	412,324
Finished Cosmetic Products		562,717			101,828
Eliminations		(114,754	)		(65,681	)
Total	$	865,781		$	448,471

Total sales:

	Three months ended					Six months ended
	June 30, 2016			June 30, 2015		June 30, 2016			June 30, 2015
Nutraceutical and Cosmetic Additives	$	266,060		$	277,353	$	551,220		$	565,630
Finished Cosmetic Products		964,937			-		2,340,055			-
Eliminations		(3,750	)		-		(23,000	)		-
Total	$	1,227,247		$	277,353	$	2,868,275		$	565,630

Net (loss) income:

	Three months ended						Six months ended
	June 30, 2016			June 30, 2015			June 30, 2016			June 30, 2015
Nutraceutical and Cosmetic Additives	$	(356,049	)	$	(21,028	)	$	(395,043	)	$	(19,362	)
Finished Cosmetic Products		199,668			-			130,503			-
Eliminations		-			-			-			-
Total	$	(156,381	)	$	(21,028	)	$	(264,540	)	$	(19,362	)

As of and for the six months ended June 30, 2015, there were no assets, sales or net loss relative to the finished cosmetic products segment.

Immudyne, Inc.

Notes to Consolidated Financial Statements

June 30, 2016

(unaudited)

2.	Summary of Significant Accounting Policies (continued)

Income Taxes

The Company files Corporate Federal and State tax returns, while Innate, which was formed as a limited liability corporation, files a separate tax return with any tax liabilities or benefits passing through to its members.

The Company records current and deferred taxes in accordance with Accounting Standards Codification (ASC) 740, “Accounting for Income Taxes.” This ASC requires recognition of deferred tax assets and liabilities for temporary differences between tax basis of assets and liabilities and the amounts at which they are carried in the financial statements, based upon the enacted rates in effect for the year in which the differences are expected to reverse. The Company establishes a valuation allowance when necessary to reduce deferred tax assets to the amount expected to be realized. The Company periodically assesses the value of its deferred tax asset, a majority of which has been generated by a history of net operating losses and determines the necessity for a valuation allowance. ASC 740 also provides a recognition threshold and measurement attribute for the financial statement recognition of a tax position taken or expected to be taken in a tax return. Using this guidance, a company may recognize the tax benefit from an uncertain tax position in its financial statements only if it is more likely-than-not (i.e., a likelihood of more than 50%) that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position.

The Company’s tax returns for all years since December 31, 2012, remain open to taxing authorities.

Stock-Based Compensation

The Company follows the provisions of ASC 718, “Share-Based Payment”. Under this guidance compensation cost generally is recognized at fair value on the date of the grant and amortized over the respective vesting periods. The fair value of options at the date of grant is estimated using the Black-Scholes option pricing model. The expected option life is derived from assumed exercise rates based upon historical exercise patterns and represents the period of time that options granted are expected to be outstanding. The expected volatility is based upon historical volatility of the Company’s shares using weekly price observations over an observation period that approximates the expected life of the options. The risk-free rate approximates the U.S. Treasury yield curve rate in effect at the time of grant for periods similar to the expected option life. Due to limited history of forfeitures, the estimated forfeiture rate included in the option valuation was zero.

Many of the assumptions require significant judgment and any changes could have a material impact in the determination of stock-based compensation expense.

Immudyne, Inc.

Notes to Consolidated Financial Statements

June 30, 2016

(unaudited)

2.	Summary of Significant Accounting Policies (continued)

Earnings (Loss) Per Share

Basic earnings (loss) per common share is based on the weighted average number of shares outstanding during each period presented. Warrants and options to purchase common stock are included as common stock equivalents only when dilutive. Potential common stock equivalents are excluded from dilutive earnings per share when the effects would be antidilutive.

Common stock equivalents comprising shares underlying 12,700,273 options and warrants for the three and six months ended June 30, 2016 have not been included in the loss per share calculation as the effects are anti-dilutive. Common stock equivalents comprising shares underlying 12,085,000 options and warrants for the three and six months ended June 30, 2015 have not been included in the loss per share calculations as the effects are anti-dilutive.

Recent Accounting Pronouncements

In March 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-09, “Compensation – Stock Compensation: Improvements to Employee Share-Based Payment Accounting,” which relates to the accounting for employee share-based payments. This standard addresses several aspects of the accounting for share-based payment award transactions, including: (a) income tax consequences; (b) classification flows of awards as either equity or liabilities; and (c) classification on the statement of cash flows. This standard will be effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. The Company is in the process of evaluating the impact of the adoption of ASU 2016-09 on its consolidated financial statements.

In February 2016, a pronouncement was issued that creates new accounting and reporting guidelines for leasing arrangements. The new guidance requires organizations that lease assets to recognize assets and liabilities on the balance sheet related to the rights and obligations created by those leases, regardless of whether they are classified as finance or operating leases. Consistent with current guidance, the recognition, measurement, and presentation of expenses and cash flows arising from a lease primarily will depend on its classification as a finance or operating lease. The guidance also requires new disclosures to help financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. The new standard is effective for annual reporting periods beginning after December 15, 2018, including interim periods within that reporting period, with early application permitted. The new standard is to be applied using a modified retrospective approach. The Company is in the process of evaluating the impact of the new pronouncement on its consolidated financial statements.

In May 2014, the Financial Accounting Standards Board ("FASB") issued accounting guidance, "Revenue from Contracts with Customers." The core principle of the new standard is for companies to recognize revenue to depict the transfer of goods or services to customers in amounts that reflect the consideration (that is, payment) to which the company expects to be entitled in exchange for those goods or services. The new standard also will result in enhanced disclosures about revenue, provide guidance for transactions that were not previously addressed comprehensively (for example, service revenue and contract modifications) and clarify guidance for multiple-element arrangements. The standard will be effective for fiscal years and interim periods within those years beginning after December 15, 2017. Accordingly, the Company will adopt this standard in the first quarter of fiscal year 2018. The Company is currently evaluating the impact this guidance will have on the consolidated financial statements.

Immudyne, Inc.

Notes to Consolidated Financial Statements

June 30, 2016

(unaudited)

2.	Summary of Significant Accounting Policies (continued)

Recent Accounting Pronouncements (continued)

In July 2015, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2015-11, “Simplifying the Measurement of Inventory.” ASU 2015-11 applies to inventory that is measured using first-in, first-out (FIFO) or average cost. An entity should measure inventory within the scope of ASU 2015-11 at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. ASU 2015-11 is effective for fiscal years beginning after December 15, 2016. The Company is in the process of evaluating the impact of this ASU on its consolidated financial statements.

In August 2014, the FASB issued ASU 2014-15, "Presentation of Financial Statements-Going Concern". This ASU is intended to define management's responsibility to evaluate whether there is substantial doubt about an organization's ability to continue as a going concern and to provide related footnote disclosures. It is effective for annual periods beginning after December 15, 2016, with early adoption permitted. The Company does not expect it to have a material effect on the Company's consolidated financial condition, results of operations, and cash flows.

All other accounting standards that have been issued or proposed by the FASB that do not require adoption until a future date are not expected to have a material impact on the consolidated financial statements upon adoption.

Fair Value of Financial Instruments

The carrying value of the Company’s financial instruments, including cash, trade accounts receivable and accounts payable and accrued expenses and notes payable approximate fair value for all periods.

Noncontrolling Interests

The Company accounts for its less than 100% interest in Immudyne PR in accordance with ASC Topic 810, Consolidation, and accordingly the Company presents noncontrolling interests as a component of equity on its consolidated balance sheet and reports the noncontrolling interest’s share of the Immudyne PR net loss attributable to noncontrolling interests in the consolidated statement of operations.

Concentration of Credit Risk

The Company grants credit in the normal course of business to its customers. The Company periodically performs credit analysis and monitors the financial condition of its customers to reduce credit risk.

The Company monitors its positions with, and the credit quality of, the financial institutions with which it invests. The Company, at times, maintains balances in various operating accounts in excess of federally insured limits.

Immudyne, Inc.

Notes to Consolidated Financial Statements

June 30, 2016

(unaudited)

2.	Summary of Significant Accounting Policies (continued)

Concentration of Credit Risk (continued)

One customer in the nutraceutical and cosmetic additives division accounted for 17% and 83% of consolidated sales for each of the three month periods ended June 30, 2016 and 2015, respectively. This customer accounted for 16% and 83% of consolidated sales for the six month periods ended June 30, 2016 and 2015, respectively. This customer accounted for 30% and 43% of accounts receivable at June 30, 2016 and December 31, 2015, respectively.

A second customer in the nutraceutical and cosmetic additives division accounted for 4% and 12% of consolidated sales for each of the three month periods ended June 30, 2016 and 2015, respectively. This customer accounted for 2% and 12% of consolidated sales for the six month periods ended June 30, 2016 and 2015, respectively. This customer accounted for 0% and 24% of accounts receivable at June 30, 2016 and December 31, 2015, respectively.

3.	Notes Payable

The Company periodically borrows from officers, directors, other related individuals and from commercial lenders. In November 2015 the Company borrowed $100,000 from a commercial lender. The loan incurs interest at 11% and is payable on November 1, 2016. Interest expense related to this loan for the three and six month ended June 30, 2016 amounted to $2,750 and $5,500, respectively. During the three and six months ended June 30, 2015 interest expense related to a loan from a second commercial lender amounted to $8,036 and $18,342, respectively.

Interest expense related to loans from officers, directors and other related individuals amounted to $313 and $248 for the six month periods ended June 30, 2016 and 2015, respectively. Interest expense amounted to $0 and $122 for the three months ended June 30, 2016 and 2015, respectively.

Total interest expense on notes payable amounted to $5,813 and $18,590 for the six months ended June 30, 2016 and 2015, respectively. Total interest expense amounted to $2,750 and $8,158 for the three months ended June 30, 2016 and 2015, respectively.

Immudyne, Inc.

Notes to Consolidated Financial Statements

June 30, 2016

(unaudited)

4.	Income Taxes

The Company is not expected to have taxable income in 2016 and incurred a loss for the year ended December 31, 2015 and accordingly, no provision for federal income tax has been made in the accompanying financial statements. At December 31, 2015, the Company had available net operating loss carryforwards of approximately $2,730,000, expiring during various years through 2035.

A summary of the deferred tax asset using an approximate 34% tax rate is as follows:

Deferred Tax Asset	$	930,000
Valuation allowance		(930,000	)
Total	$	-

The net operating loss carryforwards could be subject to limitation in any given year in the event of a change in ownership as defined by IRC Section 382.

The deferred tax benefit included in the statement of operations represents the change in the deferred tax liability at each balance sheet date.

The difference between the statutory and the effective tax rate is primarily due to a change in valuation allowance on deferred taxes, as the Company has fully reserved the deferred tax asset resulting from available net operating loss carryforwards.

5.	Stockholders’ Equity

On April 1, 2016, the Company entered into two agreements with two consultants to provide services over a nine month period in exchange for 2,300,000 shares of common stock. The Company valued the shares based on the market price on the agreement dates and for the three and six months ended June 30, 2016, the Company has recognized compensation expense of $230,000 in connection with these agreements.

Service-Based Stock Options

In May 2016, the Company issued 175,000 service-based options valued at $40,829 to two consultants at exercise prices of $0.20 per share. The options are fully vested and expire in 10 years. Accordingly, stock based compensation for the three and six months ended June 30, 2016 included $40,829 related to such options.

A Summary of the outstanding service-based options are as follows:

	Number of Options
Balance at December 31, 2015		11,025,273
Cancelled		(250,000	)
Issued		175,000

Balance at June 30, 2016		10,950,273

All outstanding options are exercisable and have a cashless exercise provision, and certain options provide for accelerated vesting provisions and modifications, as defined, if the Company is sold or acquired. The intrinsic value of options outstanding and exercisable at June 30, 2016 amounted to $747,294.

The significant assumptions used to determine the fair values of options issued, using a Black-Scholes option-pricing model are as follows:

Significant assumptions :
Risk-free interest rate at grant date		1.88	%
Expected stock price volatility		248.4	%
Expected dividend payout		—
Expected option life-years		3
Weighted average grant date fair value	$	0.24
Forfeiture rate		0	%

Immudyne, Inc.

Notes to Consolidated Financial Statements

June 30, 2016

(unaudited)

5.	Stockholders’ Equity (continued)

Service-Based Stock Options (continued)

The following is a summary of outstanding service-based options at June 30, 2016:

Exercise Price	Number of Options		Weighted Average Remaining Contractual Life

$0.10		1,680,273		2 years
$0.20 - $0.25		8,120,000		6 years
$0.40		1,150,000		5 years
Total		10,950,273

Performance-Based Stock Options

The Company had granted performance-based options to purchase 4,530,000 shares of common stock at exercise prices of $0.40 to $0.80. The options expire at various dates between 2021 and 2025 and are exercisable upon the Company achieving annual sales revenue of $5,000,000 and $10,000,000. The fair value of these performance-based options aggregated $135,567 to be expensed over the implicit service period commencing once management believes the performance criteria will be met.

Management believes the performance criteria for options exercisable upon the Company achieving annual sales revenue of $5,000,000, with a fair value amounting to $116,600, will be met during the year ended December 31, 2016. Accordingly, stock based compensation expense for the three and six months ended June 30, 2016 includes $38,867 and $77,733, respectively, related to such options. At June 30, 2016, the unearned compensation for all the performance based options is $57,834.

Stock based compensation expense amounted to $309,695 and $2,000 for the three month periods ended June 30, 2016 and 2015, respectively. Stock based compensation expense amounted to $348,562 and $4,000 for the six month periods ended June 30, 2016 and 2015, respectively. Such amounts are included in compensation and related expenses in the accompanying statement of operations.

Warrants

Warrants outstanding and exercisable amounted to 1,750,000 at December 31, 2015 and June 30, 2016. The weighted average exercise price of warrants outstanding at June 30, 2016 is $0.16. The warrants expire during November 2016 and December 2017.

Immudyne, Inc.

Notes to Consolidated Financial Statements

June 30, 2016

(unaudited)

6.	Royalties

The Company was subject to a royalty agreement based upon sales of certain skin care products. The agreement required the Company to pay a royalty based upon 8% of such sales, up to $227,175. During the year ended December 31, 2015 the Company’s sales reached the maximum amount under which the Company was required to pay a royalty under this agreement. Royalty expense amounted to $-0- and $1,157 for the three month periods ended June 30, 2016 and 2015, respectively. Royalty expense amounted to $-0- and $20,157 for the six month periods ended June 30, 2016 and 2015, respectively. During December 2015, the Company’s President who had a 60% interest in the royalties, converted royalties payable under the agreement in the amount of $84,868 to 499,225 shares of Company stock at 0.17 cents per share.

Included in accounts payable and accrued expenses at June 30, 2016 and December 31, 2015 was $56,579 in regards to this agreement.

7.	Commitments and Contingencies

Leases

The Company leases a plant in Kentucky under an operating lease which expired on May 31, 2016. Management is currently discussing renewal lease options for the Kentucky plant and is operating on a month-to-month lease arrangement until a final agreement has been accepted. Monthly base rental payments are approximately $9,000. In addition, Immudyne PR operates in Puerto Rico in space owned by one of the parties to the joint venture. Rent expense for the three month periods ended June 30, 2016 and 2015, was $27,284 and $14,468, respectively. Rent expense for the six month periods ended June 30, 2016 and 2015, was $43,900 and $34,929, respectively.

Employment and Consulting Agreements

The Company has entered into various agreements with officers, directors, employees and consultants that expire in one to five years. The agreements provide for annual compensation of up to $145,000 and the issuance of stock options, at exercise prices of $0.40 and $0.80, to purchase 4,530,000 shares of common stock issuable upon the Company’s revenue exceeding $5,000,000 and $10,000,000, as defined. In addition, the agreements provide for bonus compensation to these individuals aggregating up to 15% (with no individual having more than 5%) of the Company’s pretax income.

Restricted Stock and Options

The Company has entered into two agreements on April 1, 2016 with two consultants of Immudyne PR for business development, marketing and sales related services (the “Consultant Agreements”). Upon signing, each consultant was issued 1,000,000 restricted shares of Immudyne, Inc. common stock. In addition, each consultant shall receive an additional 150,000 restricted shares of Immudyne, Inc. common stock for each $500,000 distributed by Immudyne PR to the Company. For each consultant the amount of shares to be issued by the Company to the consultants shall be capped at 1,500,000 restricted shares when Immudyne PR has transferred $5,000,000 to the Company, for a combined capped total of 3,000,000 restricted shares. For the three and six months ended June 30, 2016, 2,300,000 restricted shares of common stock have been issued related to these agreements.

Immudyne, Inc.

Notes to Consolidated Financial Statements

June 30, 2016

(unaudited)

7.	Commitments and Contingencies (continued)

Restricted Stock and Options (continued)

In addition, the Consulting Agreements provided that each consultant shall receive a bonus of an additional 750,000 restricted shares of Immudyne Inc. common stock, plus an option to buy 1,000,000 shares of Immudyne, Inc. common stock at $0.20/share (including a cashless exercise feature) when Immudyne PR has transferred to the Company at each of the following three (3) thresholds: $1,250,000, $2,000,000 and $3,000,000 for a total of 2,250,000 of restricted shares of Immudyne, Inc. common stock and options to purchase up to 3,000,000 shares of Immudyne, Inc. common stock at $0.20/share. As of June 30, 2016, no bonus shares have been issued and no options have been granted under this agreement.

Legal Matters

In the normal course of business operations the Company may become involved in various legal matters. At June 30, 2016, the Company’s management does not believe that there are any potential legal matters that could have an adverse effect on the Company’s financial position.

8.	Related Party Transactions

For the three and six months ended June 30, 2016 one of the Company’s directors, acting as an advisor for the Company, provided legal and business advisory services and was compensated $3,000 and $9,000, respectively. In addition, for the three and six months ended June 30, 2016 the Company’s President received $6,000 and $14,000, respectively, for reimbursement of home office expenditures, including rent, utilities and other related expenses for two offices.

9.	Subsequent Events

The Company has evaluated subsequent events through the date these financial statements were issued. On July 1, 2016 the Company issued 50,000 service-based options to a consultant at an exercise prices of $0.20 per share. The options are fully vested and expire in 10 years. In addition, the Company granted performance-based options to purchase 150,000 shares of common stock at exercise prices of $0.40 to $0.80. The options expire in 10 years and are exercisable upon the Company achieving annual sales revenue between $5,000,000 and $10,000,000.

* * * * *

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Overview

We manufacture, distribute and sell natural immune support products; namely proprietary yeast beta glucans which are natural extracts that have been shown through testing and analysis and scientific research to support the immune system. Yeast beta glucans are classified as generally recognized as safe (“GRAS”) by the Food and Drug Administration (“FDA”). We are and have been a science driven company for more than 25 years. Our products are used in oral and topical applications. Historically, we have sold our proprietary additives, for both oral and topical use, primarily via business-to-business to large dietary supplement and cosmetic companies. During fiscal year 2015 we have seen increased interest in our proprietary GRAS topical delivery system, which we believe may have additional beneficial and marketable uses (both topically and orally) and on which are conducting further testing. In addition, during the fourth quarter of 2015, we established a joint venture, that does business under the name Inate Scientific LLC (“Inate”), to launch a complete skin care regimen that contains our proprietary ingredients and which contributed to our revenues in the first six months of 2016. The Company entered into a limited liability company operating agreement with its joint venture partners with respect to Inate under the legal name Immudyne PR LLC (“Immudyne PR”). On April 1, 2016, the original operating agreement was amended and restated and we increased our ownership and voting interest in Immudyne PR to 78.16667%. As a result of our ownership and control of Immudyne PR, we now operate in two business segments, nutraceutical and cosmetic additives and finished cosmetic products.

We have performance based contracts with our sales and marketing executives, which allows us to continue to maintain a relatively low overhead. Our priority is to pursue opportunities to market our products and increase sales. We expect that a significant component of our selling, general and administration expenses going forward will consist of equipment leasing costs relating to improving our operating efficiencies, as well as conducting new studies which could open new markets. These aforementioned costs, along with the additional costs resulting from our operations as a public reporting company, could adversely impact our future results of operations. Additional significant factors that we believe will affect our operating results going forward are: (i) protection of our intellectual property rights; (ii) imposition of more stringent government regulations of our products; and (iii) marketing expenses.

We historically have expended a significant amount of our funds on obtaining and protecting our patents, trade secrets and proprietary products. We rely on the patent and trademark protection laws in the U.S. to protect our intellectual property and maintain our competitive position in the marketplace. For several years, we were involved in complex litigation regarding patents and licenses critical to our products. In 2010, we prevailed on all major legal matters and reached favorable settlements. If additional litigation becomes necessary to protect our intellectual property rights, such litigation may be costly, divert our management’s attention away from our core business and have a negative impact on our operations. Furthermore, there is no guarantee that litigation would result in an outcome favorable to us. In addition, yeast beta glucans are designated as GRAS under current FDA regulations. Future government regulations may prevent or delay the introduction or require the reformulation of our products. Some agencies, such as the FDA, could require us to remove a particular product from the market, delay or prevent the import of raw materials for the manufacture of our products or otherwise disrupt the marketing of our products. Any such government actions could result in additional costs to us, reduced growth prospects, lost sales from products that we are required to remove from the market and potential product liability litigation.

We have historically operated with limited capital and have funded operations in the past through the sales of our products and loans and advances from Mark McLaughlin, our President, and other directors. In 2015 we entered into a non-dilutive short term loan agreement with an investor for $100,000 and secured additional loans of $30,000 from our President and $75,000 from a greater than 5% shareholder of the Company. These loans were satisfied in full as of December 31, 2015. In addition, in November 2015, we established a $100,000 line of credit with a commercial lender for our short-term working capital needs. We also had approximately $400,000 in holdbacks as of June 30, 2016, which is being released to us a monthly basis. We plan on our operating business (in conjunction with our short term non-dilutive borrowings) to be able to fund operations through 2016. However, in the event we require additional operating capital we will have to depend on sources other than operating revenues to meet our operating and capital needs. No assurance can be given that such sources will be available and no assurance can be given that Mr. McLaughlin or other directors who have in the past willingly funded operations will commit to do so in the future, or that we will be successful in our endeavors to raise additional capital. For additional information regarding these and other risks please see our Annual Report on Form 10K for the fiscal year ended December 31, 2015 filed with the SEC on March 30, 2016.

Results of Operations

Three Months Ended June 30, 2016, Compared to the Three Months Ended June 30, 2015

The following table sets forth the results of our operations for the periods indicated as a percentage of net sales:

2016 2015

$ % of Sales $ % of Sales

Sales 1,227,247 277,353

Cost of sales 700,977 57 % 89,503 32 %

Gross profit 526,270 43 % 187,850 68 %

Operating expenses (679,902 ) (55 )% (205,020 ) (74 )%

Loss from operations (153,632 ) (13 )% (17,170 ) (6 )%

Other (expenses) (2,750 ) 0 % (8,158 ) (3 )%

Income tax benefit - 0 % 4,300 2 %

Net income (loss) (156,382 ) (13 )% (21,028 ) (8 )%

Net income (loss) attributable to noncontrolling interests 43,594 4 % - 0 %

Net income (loss) attributable to Immudyne, Inc. (199,976 ) (16 )% (21,028 ) (8 )%

Overall sales for the three months ended June 30, 2016 were $1.23 million, an increase of 342% from $0.28 million for the same period in 2015. Our increase in sales was primarily attributable to sales made by our finished cosmetic products segment of $1 million through our joint venture with Inate, which did not operate in the period ended June 30, 2015. Net sales for our nutraceutical and cosmetic additives segment remained relatively consistent between periods at $0.3 million and were in line with our expectations.

Cost of sales consists primarily of material costs, labor costs, marketing costs and related overhead directly attributable to the production of our products. Total cost of sales increased 683% to $0.70 million in the second quarter of 2016 compared to $0.09 million for the same period in 2015, which costs in the 2015 period were solely attributable to our nutraceutical and cosmetic additives product segment. The increase in our cost of sales was due to our increased advertising and marketing expenses incurred to generate our significant increase in sales from our finished cosmetic products segment, which costs were not incurred in the second quarter of 2015.

Gross profit increased 180% to $0.53 million in the second quarter of 2016 compared to $0.19 million for the same period in 2015 as a result of our increased sales offset by our advertising and marketing expenses for the quarter. Gross profit as a percentage of sales decreased to 43% in the second quarter of 2016 from 68% for the same period in 2015 due to the shift in the composition of our sales between periods from solely topical and oral additives to primarily finished products sold through Inate, which products generally have lower margins.

Operating expenses consisted of general and administrative expense, compensation and related expense and professional fees. Overall operating expenses increased 232% to $0.68 million in the second quarter of 2016 from $0.21 million for the same period in 2015, primarily due to increased compensation related expenses with respect to shares issued to the Company’s joint venture partners pursuant to previously disclosed service agreements. The increase in our overall operating expenses was also due to our increase in sales. General and administration expense increased 24% to $0.08 million in the second quarter of 2016 from $0.06 million for the same period in 2015. Compensation and related expense increased 314% to $0.48 million in the second quarter of 2016 from $0.11 million for the same period in 2015 due to the aforementioned share issuance. Professional fees increased 376% to $0.13 million in the second quarter of 2016 from approximately $0.03 million for the same period in 2015, due to increased legal and accounting fees incurred with respect to Inate’s operations.

Net loss attributable to Immudyne in the second quarter of 2016 was approximately $0.20 million compared to net loss of $0.02 million for the same period in 2015. We consolidated the operations of our joint venture, Inate, and reflected a non-controlling interest for 21.833% of these operations. Net loss attributable to Immudyne, Inc. as a percentage of sales was 16% in the second quarter of 2016 compared to net loss as a percentage of sales of 8% for the same period in 2015. Our net loss notwithstanding our substantial increase in sales was primarily due to the advertising and marketing expenses we incurred in the quarter to help generate sales and our increased compensation expenses due to shares issued to the Company’s joint venture partners pursuant to previously disclosed service agreements. We believe these costs will decrease as a percentage of sales over the course of the fiscal year as Inate continues to mature as a business.

Six Months Ended June 30, 2016, Compared to the Six Months Ended June 30, 2015

The following table sets forth the results of our operations for the periods indicated as a percentage of net sales:

	2016						2015
	$			% of Sales			$			% of Sales
Sales		2,868,275						565,630
Cost of sales		2,038,919			71	%		163,719			29	%
Gross profit		829,356			29	%		401,911			71	%
Operating expenses		(1,088,084	)		(38	)%		(411,247	)		(73	)%
Loss from operations		(258,728	)		(9	)%		(9,336	)		(2	)%
Other income (expenses), net		(5,813	)		0	%		(18,626	)		(3	)%
Income tax benefit		-			0	%		8,600			2	%
Net income (loss)		(264,541	)		(9	)%		(19,362	)		(3	)%
Net income (loss) attributable to noncontrolling interest		(2,516	)		0	%		-			0	%
Net income (loss) attributable to Immudyne, Inc.		(262,025	)		(9	)%		(19,362	)		(3	)%

Overall sales for the six months ended June 30, 2016 were $2.87 million, an increase of 407% from $0.57 million for the same period in 2015. Our increase in sales was primarily attributable to sales made by our finished cosmetic products segment of $2.34 million through our joint venture with Inate, which did not operate in the period ended June 30, 2015. Net sales for our nutraceutical and cosmetic additives segment remained relatively consistent between periods at $0.6 million and were in line with our expectations.

Cost of sales consists primarily of material costs, labor costs, marketing costs and related overhead directly attributable to the production of our products. Total cost of sales increased 1,145% to $2.04 million for the six months ended June 30, 2016 compared to $0.16 million for the same period in 2015, which costs in the 2015 period were solely attributable to our nutraceutical and cosmetic additives product segment. The increase in our cost of sales was due to our significant up-front advertising and marketing expenses ($1.16 million) incurred to generate our significant increase in sales from our finished cosmetic products segment, which costs were not incurred in the 2015 period.

Gross profit increased 106% to $0.83 million in the six months ended June 30, 2016 compared to $0.40 million for the same period in 2015 as result of our increased sales offset by our significant up-front advertising and marketing expenses in the 2016 period. Gross profit as a percentage of sales decreased to 29% for the six months ended June 30, 2016 from 71% for the same period in 2015 due to the shift in the composition of our sales between periods from solely topical and oral additives to primarily finished products through Inate, which products generally have lower margins.

Operating expenses consisted of general and administrative expense, compensation and related expense and professional fees. Overall operating expenses increased 165% to $1.09 million in the six months ended June 30, 2016 from $0.41 million for the same period in 2015. The increase in our overall operating expenses was due primarily to our operation of Inate in the 2016 year whereas we only had operations in our nutraceutical and cosmetic additives segment in the comparable 2015 period. General and administration expense increased 19% to $0.18 million for the six months ended June 30, 2016 from $0.15 million for the same period in 2015. Compensation and related expense increased 257% to $0.72 million in the six months ended June 30, 2016 from $0.20 million for the same period in 2015 due primarily to increased compensation related expenses with respect to shares issued to the Company’s joint venture partners pursuant to previously disclosed service agreements. Professional fees increased 215% to $0.19 million for the six months ended June 30, 2016 from approximately $0.06 million for the same period in 2015, due to increased legal and accounting fees incurred with respect to Inate’s operations.

Net loss attributable to Immudyne in the six months ended June 30, 2016 was approximately $0.26 million compared to net loss of $0.02 million for the same period in 2015. We consolidated the operations of our joint venture, Inate, and reflected a non-controlling interest for 21.833% of these operations. Net loss attributable to Immudyne, Inc. as a percentage of sales was 9% in six months ended June 30, 2016 compared to net loss as a percentage of sales of 3% for the same period in 2015. Our net loss notwithstanding our substantial increase in sales was primarily due to the substantial up-front advertising and marketing expenses we incurred in the first quarter to help generate sales through our recently formed joint venture, Inate, and our increased compensation expenses due to shares issued to the Company’s joint venture partners pursuant to previously disclosed service agreements. We believe these costs will decrease as a percentage of sales over the course of the fiscal year as Inate continues to mature as a business.

Liquidity and Capital Resources

Our principal demands for liquidity are to increase sales, purchase inventory and for sales distribution and general corporate purposes. We incurred negative operating cash flows in the 2015 and 2014 fiscal years and for the first two quarters of 2016. As a result, our auditors have raised substantial doubt about our ability to continue as a going concern. We plan on our operating business (in conjunction with our short term non-dilutive borrowings) being able to fund operations through 2016. However, if necessary, we may raise additional capital through a private placement of common stock, obtaining debt financing or from advances from our President and/or directors; however no assurances can be made that we will be successful in our endeavors to raise additional capital.

In 2015 we entered into a non-dilutive short term loan agreement with an investor for $100,000 and secured additional loans of $30,000 from our President and $75,000 from a greater than 5% shareholder of the Company. These loans were satisfied in full as of December 31, 2015. In addition, in November 2015, we secured a $100,000 line of credit with a commercial lender for our short-term working capital needs, which amount was outstanding in full as of December 31, 2015 and March 31, 2016. The amounts borrowed under the line of credit bear interest at 11% per annum and all amounts are payable on November 1, 2016. We also had approximately $400,000 in holdbacks as of June 30, 2016, which are being released to us a monthly basis.

There can be no assurance that required future financing can be successfully completed on a timely basis, or on terms acceptable to us. Any future issuance of equity securities could cause dilution to our shareholders. Any incurrence of indebtedness would increase our debt service obligations and would cause us to be subject to restrictive operating and financial covenants.

We had net working capital of approximately $344,000 at June 30, 2016, resulting in an increase from net working capital of approximately ($176,321) at June 30, 2015. The ratio of current assets to current liabilities was 1.6 to 1 at June 30, 2016.

The following is a summary of cash provided by or used in each of the indicated types of activities during the six months ended June 30, 2016 and 2015:

	2016			2015
Cash provided by (used in):
Operating activities	$	(76,662	)	$	(56,433	)
Financing activities		79,130			60,486

Net cash flow used by operating activities was $0.08 million for the six months ended June 30, 2016, compared to net cash flow used in operating activities of $0.06 million for the same period in 2015. The increase in the amount of cash used by our operating activities was due to up-front advertising and marketing expenses incurred in the 2016 period. We expect that these expenses will decrease as a percentage of sales over the course of the fiscal year as Inate continues to mature as a business.

Net cash flows provided by financing activities was $0.08 million for the six months ended June 30, 2016, compared to net cash flows provided by financing activities of $0.06 million for the same period in 2015.

Indebtedness

From time to time, our directors, officers and other related individuals have made short-term advances to us for our operating needs. In 2015 we entered into a non-dilutive short term loan agreement with an investor for $100,000 and secured additional loans of $30,000 from our President and $75,000 from a greater than 5% shareholder of the Company. These loans were satisfied in full as of December 31, 2015. In addition, in November 2015, we secured a $100,000 line of credit with a commercial lender for our short-term working capital needs, which amount is outstanding in full as of December 31, 2015 and June 30, 2016. The amounts borrowed under the line of credit bear interest at 11% per annum and all amounts are payable on November 1, 2016.

We are subject to a royalty agreement pursuant to which we are required to pay a monthly royalty of 8% on all sales of certain skin care products up to $227,175. During the year ended December 31, 2015 our sales reached the maximum amount under which we are required to pay a royalty under this agreement. Royalty expense amounted to $0 and $20,157 for the six months ended June 30, 2016 and 2015, respectively. During 2015, our President, who has a 60% interest in the royalties, converted all royalties payable (in the amount of $84,868) to 499,225 shares of the company’s stock valued at $0.17 cents a share.

Off-Balance Sheet Arrangements

There are no off-balance sheet arrangements between us and any other entity that have, or are reasonably likely to have, a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to shareholders.

We have not entered into any financial guarantees or other commitments to guarantee the payment obligations of any third parties. We have not entered into any derivative contracts that are indexed to our shares and classified as stockholders’ equity or that are not reflected in our consolidated financial statements. Furthermore, we do not have any retained or contingent interest in assets transferred to an unconsolidated entity that serves as credit, liquidity or market risk support to such entity. We do not have any variable interest in any unconsolidated entity that provides financing, liquidity, market risk or credit support to us or engages in leasing, hedging or research and development services with us.

Critical Accounting Policies

While our significant accounting policies are described more fully in Note 2 to our financial statements, we believe the following accounting policies are the most critical to aid you in fully understanding and evaluating this management discussion and analysis.

Basis of Presentation and Use of Estimates

The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the U.S., or U.S. GAAP. In preparing financial statements in conformity with U.S. GAAP, management makes estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the dates of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period. Significant estimates required by management include the valuation of inventory and stockholders’ equity-based transactions. Actual results could differ from those estimates.

Inventory

Inventory is valued at the lower of cost or market value with cost determined on a first-in, first-out basis. Management compares the cost of inventory with the net realizable value and an allowance is made for writing down their inventories to market value, if lower.

Revenue Recognition

Delivery is considered to have occurred when title and risk of loss have transferred to the customer. If title does not pass until the product reaches the customer’s delivery site, then recognition of revenue is deferred until that time. There are no formal sales incentives offered to any of the Company’s customers. Volume discounts may be offered from time to time to customers purchasing large quantities on a per transaction basis.

Stock-based Compensation

The Company follows the provisions of ASC 718, “Share-Based Payment”. Under this guidance compensation cost generally is recognized at fair value on the date of the grant and amortized over the respective vesting periods. The fair value of options at the date of grant is estimated using the Black-Scholes option pricing model. The expected option life is derived from assumed exercise rates based upon historical exercise patterns and represents the period of time that options granted are expected to be outstanding. The expected volatility is based upon historical volatility of our shares using weekly price observations over an observation period that approximates the expected life of the options. The risk-free rate approximates the U.S. Treasury yield curve rate in effect at the time of grant for periods similar to the expected option life. Due to limited history of forfeitures, estimated forfeiture rate included in the option valuation was zero. Many of the assumptions require significant judgment and any changes could have a material impact in the determination of stock-based compensation expense.

Noncontrolling Interests

The Company accounts for its less than 100% interest in Inate Scientific in accordance with ASC Topic 810, Consolidation, and accordingly the Company presents noncontrolling interests as a component of equity on its consolidated balance sheet and reports the noncontrolling interest’s share of Inate net loss attributable to noncontrolling interests in the consolidated statement of operations.

New Accounting Pronouncements

In March 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-09, “Compensation – Stock Compensation: Improvements to Employee Share-Based Payment Accounting,” which relates to the accounting for employee share-based payments. This standard addresses several aspects of the accounting for share-based payment award transactions, including: (a) income tax consequences; (b) classification of awards as either equity or liabilities; and (c) classification on the statement of cash flows. This standard will be effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. The Company is in the process of evaluating the impact of the adoption of ASU 2016-09 on its consolidated financial statements.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

Not applicable.

Item 4. Controls and Procedures

Disclosure Controls and Procedures

We carried out an evaluation, under the supervision and with the participation of our Principal Executive Officer (“PEO”), who is also our Principal Financial Officer (“PFO”), of the design and effectiveness of our “disclosure controls and procedures” (as defined under Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934) as of the end of the period covered by this report. Based on this evaluation, our PEO/PFO concluded that as of the end of the period covered by this report, these disclosure controls and procedures were not effective. The conclusion that our disclosure controls and procedures were not effective was due to the presence of the following material weaknesses in disclosure controls and procedures which are indicative of many small companies with small staff: (i) inadequate segregation of duties and effective risk assessment as the Company had only one officer; (ii) insufficient written policies and procedures for accounting and financial reporting with respect to the requirements and application of both US GAAP and SEC Guidelines; and (iii) inadequate security and restricted access to computer systems including insufficient disaster recovery plans; and (iv) no written whistleblower policy. If and when sufficient funds are available, our PEO/PFO plans to implement appropriate disclosure controls and procedures to remediate these material weaknesses, including (i) appointing additional qualified personnel to address inadequate segregation of duties and ineffective risk management; (ii) adopt sufficient written policies and procedures for accounting and financial reporting and a whistle blower policy; and (iii) implement sufficient security and restricted access measures regarding our computer systems and implement a disaster recovery plan.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) that occurred during the quarter ended June 30, 2016, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply its judgment in evaluating the benefits of possible controls and procedures relative to their costs.

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

We may become involved in various lawsuits and legal proceedings arising in the ordinary course of business. Litigation is subject to inherent uncertainties and an adverse result in these or other matters may arise from time to time that may have an adverse effect on our business, financial conditions or operating results. We are currently not aware of any such legal proceedings or claims that will have, individually or in the aggregate, a material adverse effect on our business, financial condition or operating results.

Item 1A. Risk Factors

You should consider carefully the factors discussed in the “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2015.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

None.

Item 6. Exhibits

See the Exhibit Index following the signature page to this Quarterly Report on Form 10-Q for a list of exhibits filed or furnished with this report, which Exhibit Index is incorporated herein by reference.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	IMMUDYNE INC.
	(Registrant)

Date: August 15, 2016	By:	/s/ Mark McLaughlin
		Mark McLaughlin
		Chief Executive Officer
		(Principal Executive Officer)

EXHIBIT INDEX

Exhibit No.		Document Description
31.1 †		Certification of Principal Executive Officer and Principal Financial Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1 ‡		Certifications of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS†		XBRL Instance Document
101.SCH†		XBRL Schema Document
101.CAL†		XBRL Calculation Linkbase Document
101.DEF†		XBRL Definition Linkbase Document
101.LAB†		XBRL Label Linkbase Document
101.PRE†		XBRL Presentation Linkbase Document

† Filed herewith

‡ Furnished herewith

EX-31.1 2 f10q0616ex31i_immudyne.htm CERTIFICATION

Exhibit 31.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

PURSUANT TO SECTION 302(a)

OF THE SARBANES-OXLEY ACT OF 2002

I, Mark McLaughlin, certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q for the period ended June 30, 2016, of Immudyne, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 15, 2016	By:	/s/ Mark McLaughlin
		Mark McLaughlin
		(Principal Executive Officer and Principal Financial Officer)

EX-32.1 3 f10q0616ex32i_immudyne.htm CERTIFICATION

Exhibit 32.1

CERTIFICATIONS OF PRESIDENT AND PRINCIPAL FINANCIAL OFFICER

PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Mark McLaughlin, hereby certify that, to the best of my knowledge, the Quarterly Report on Form 10-Q of Immudyne, Inc. for the quarterly period ended June 30, 2016, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Quarterly Report on Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of Immudyne Inc.

Date: August 15, 2016	By:	/s/ Mark McLaughlin
		Mark McLaughlin
		(Principal Executive Officer and Principal Financial Officer)

EX-101.INS 4 immd-20160630.xml XBRL INSTANCE FILE 0000948320 2014-12-31 0000948320 2015-04-01 2015-06-30 0000948320 us-gaap:AccountsReceivableMember immd:OneCustomerMember immd:NutraceuticalAndCosmeticMember 2015-04-01 2015-06-30 0000948320 us-gaap:AccountsReceivableMember immd:SecondCustomerMember immd:NutraceuticalAndCosmeticMember 2015-04-01 2015-06-30 0000948320 us-gaap:BoardOfDirectorsChairmanMember 2015-04-01 2015-06-30 0000948320 immd:NutraceuticalAndCosmeticMember 2015-04-01 2015-06-30 0000948320 immd:CosmeticGoodsMember 2015-04-01 2015-06-30 0000948320 us-gaap:IntersegmentEliminationMember 2015-04-01 2015-06-30 0000948320 us-gaap:SalesMember immd:OneCustomerMember immd:NutraceuticalAndCosmeticMember 2015-04-01 2015-06-30 0000948320 us-gaap:SalesMember immd:SecondCustomerMember immd:NutraceuticalAndCosmeticMember 2015-04-01 2015-06-30 0000948320 immd:PerformanceBasedStockOptionsMember 2015-04-01 2015-06-30 0000948320 us-gaap:EmployeeStockOptionMember us-gaap:WarrantMember 2015-04-01 2015-06-30 0000948320 2015-01-01 2015-06-30 0000948320 us-gaap:BoardOfDirectorsChairmanMember 2015-01-01 2015-06-30 0000948320 immd:NutraceuticalAndCosmeticMember 2015-01-01 2015-06-30 0000948320 immd:CosmeticGoodsMember 2015-01-01 2015-06-30 0000948320 us-gaap:IntersegmentEliminationMember 2015-01-01 2015-06-30 0000948320 us-gaap:SalesMember immd:OneCustomerMember immd:NutraceuticalAndCosmeticMember 2015-01-01 2015-06-30 0000948320 us-gaap:SalesMember immd:SecondCustomerMember immd:NutraceuticalAndCosmeticMember 2015-01-01 2015-06-30 0000948320 immd:PerformanceBasedStockOptionsMember 2015-01-01 2015-06-30 0000948320 us-gaap:EmployeeStockOptionMember us-gaap:WarrantMember 2015-01-01 2015-06-30 0000948320 2015-06-30 0000948320 2015-11-30 0000948320 2015-11-02 2015-11-30 0000948320 2015-01-01 2015-12-31 0000948320 us-gaap:AccountsReceivableMember immd:OneCustomerMember 2015-01-01 2015-12-31 0000948320 us-gaap:AccountsReceivableMember immd:SecondCustomerMember 2015-01-01 2015-12-31 0000948320 us-gaap:PresidentMember 2015-01-01 2015-12-31 0000948320 2015-12-31 0000948320 immd:NutraceuticalAndCosmeticMember 2015-12-31 0000948320 immd:CosmeticGoodsMember 2015-12-31 0000948320 us-gaap:IntersegmentEliminationMember 2015-12-31 0000948320 us-gaap:PresidentMember 2015-12-31 0000948320 us-gaap:EmployeeStockOptionMember 2015-12-31 0000948320 us-gaap:WarrantMember 2015-12-31 0000948320 us-gaap:CommonStockMember 2015-12-31 0000948320 us-gaap:AdditionalPaidInCapitalMember 2015-12-31 0000948320 us-gaap:RetainedEarningsMember 2015-12-31 0000948320 immd:SummationMember 2015-12-31 0000948320 us-gaap:NoncontrollingInterestMember 2015-12-31 0000948320 immd:ImmudynePrLlcMember 2016-04-01 0000948320 us-gaap:RestrictedStockMember 2016-03-25 2016-04-01 0000948320 immd:ConsultantMember 2016-03-25 2016-04-01 0000948320 us-gaap:EmployeeStockOptionMember 2016-05-01 2016-05-31 0000948320 2016-03-31 2016-06-30 0000948320 us-gaap:AccountsReceivableMember immd:OneCustomerMember immd:NutraceuticalAndCosmeticMember 2016-03-31 2016-06-30 0000948320 us-gaap:AccountsReceivableMember immd:SecondCustomerMember immd:NutraceuticalAndCosmeticMember 2016-03-31 2016-06-30 0000948320 us-gaap:BoardOfDirectorsChairmanMember 2016-03-31 2016-06-30 0000948320 immd:NutraceuticalAndCosmeticMember 2016-03-31 2016-06-30 0000948320 immd:CosmeticGoodsMember 2016-03-31 2016-06-30 0000948320 us-gaap:IntersegmentEliminationMember 2016-03-31 2016-06-30 0000948320 us-gaap:SalesMember immd:OneCustomerMember immd:NutraceuticalAndCosmeticMember 2016-03-31 2016-06-30 0000948320 us-gaap:SalesMember immd:SecondCustomerMember immd:NutraceuticalAndCosmeticMember 2016-03-31 2016-06-30 0000948320 us-gaap:EmployeeStockOptionMember 2016-03-31 2016-06-30 0000948320 immd:PerformanceBasedStockOptionsMember 2016-03-31 2016-06-30 0000948320 us-gaap:EmployeeStockOptionMember us-gaap:WarrantMember 2016-03-31 2016-06-30 0000948320 2016-01-01 2016-06-30 0000948320 us-gaap:BoardOfDirectorsChairmanMember 2016-01-01 2016-06-30 0000948320 immd:NutraceuticalAndCosmeticMember 2016-01-01 2016-06-30 0000948320 immd:CosmeticGoodsMember 2016-01-01 2016-06-30 0000948320 us-gaap:IntersegmentEliminationMember 2016-01-01 2016-06-30 0000948320 us-gaap:SalesMember immd:OneCustomerMember immd:NutraceuticalAndCosmeticMember 2016-01-01 2016-06-30 0000948320 us-gaap:SalesMember immd:SecondCustomerMember immd:NutraceuticalAndCosmeticMember 2016-01-01 2016-06-30 0000948320 us-gaap:AccountsReceivableMember immd:OneCustomerMember 2016-01-01 2016-06-30 0000948320 us-gaap:AccountsReceivableMember immd:SecondCustomerMember 2016-01-01 2016-06-30 0000948320 us-gaap:EmployeeStockOptionMember 2016-01-01 2016-06-30 0000948320 us-gaap:WarrantMember 2016-01-01 2016-06-30 0000948320 us-gaap:CommonStockMember 2016-01-01 2016-06-30 0000948320 us-gaap:AdditionalPaidInCapitalMember 2016-01-01 2016-06-30 0000948320 us-gaap:RetainedEarningsMember 2016-01-01 2016-06-30 0000948320 immd:SummationMember 2016-01-01 2016-06-30 0000948320 us-gaap:NoncontrollingInterestMember 2016-01-01 2016-06-30 0000948320 us-gaap:RestrictedStockMember 2016-01-01 2016-06-30 0000948320 immd:PerformanceBasedStockOptionsMember 2016-01-01 2016-06-30 0000948320 immd:PerformanceBasedStockOptionsMember us-gaap:MinimumMember 2016-01-01 2016-06-30 0000948320 immd:PerformanceBasedStockOptionsMember us-gaap:MaximumMember 2016-01-01 2016-06-30 0000948320 immd:ExercisePriceRangeOneMember 2016-01-01 2016-06-30 0000948320 immd:ExercisePriceRangeTwoMember 2016-01-01 2016-06-30 0000948320 immd:ExercisePriceRangeThreeMember 2016-01-01 2016-06-30 0000948320 us-gaap:EmployeeStockOptionMember us-gaap:WarrantMember 2016-01-01 2016-06-30 0000948320 2016-06-30 0000948320 immd:NutraceuticalAndCosmeticMember 2016-06-30 0000948320 immd:CosmeticGoodsMember 2016-06-30 0000948320 us-gaap:IntersegmentEliminationMember 2016-06-30 0000948320 us-gaap:EmployeeStockOptionMember 2016-06-30 0000948320 us-gaap:WarrantMember 2016-06-30 0000948320 us-gaap:CommonStockMember 2016-06-30 0000948320 us-gaap:AdditionalPaidInCapitalMember 2016-06-30 0000948320 us-gaap:RetainedEarningsMember 2016-06-30 0000948320 immd:SummationMember 2016-06-30 0000948320 us-gaap:NoncontrollingInterestMember 2016-06-30 0000948320 immd:PerformanceBasedStockOptionsMember 2016-06-30 0000948320 immd:ExercisePriceRangeOneMember 2016-06-30 0000948320 immd:ExercisePriceRangeTwoMember 2016-06-30 0000948320 immd:ExercisePriceRangeThreeMember 2016-06-30 0000948320 immd:ExercisePriceRangeTwoMember us-gaap:MinimumMember 2016-06-30 0000948320 immd:ExercisePriceRangeTwoMember us-gaap:MaximumMember 2016-06-30 0000948320 us-gaap:SubsequentEventMember immd:PerformanceBasedStockOptionsMember us-gaap:MinimumMember 2016-07-01 0000948320 us-gaap:SubsequentEventMember immd:PerformanceBasedStockOptionsMember us-gaap:MaximumMember 2016-07-01 0000948320 us-gaap:SubsequentEventMember immd:PerformanceBasedStockOptionsMember us-gaap:MinimumMember 2016-06-29 2016-07-01 0000948320 us-gaap:SubsequentEventMember immd:PerformanceBasedStockOptionsMember us-gaap:MaximumMember 2016-06-29 2016-07-01 0000948320 us-gaap:SubsequentEventMember us-gaap:ServiceAgreementsMember 2016-06-29 2016-07-01 0000948320 us-gaap:SubsequentEventMember immd:PerformanceBasedStockOptionsMember 2016-06-29 2016-07-01 0000948320 2016-08-15 xbrli:shares iso4217:USD iso4217:USDxbrli:shares xbrli:pure immd:Consultants Immudyne, Inc. 0000948320 false --12-31 10-Q 2016-06-30 2016 Q2 Smaller Reporting Company 34310375

75495

79548

232984

235452

154436

451074

61051

179255

448471

865781

167481

421640

100000

267481

521640

320103

343103

8366313

8783487

-8586338

-8848363

100078

278227

80912

65914

180990

320103

8366313

-8586338

100078

80912

344141

343103

8783487

-8848363

278227

65914

448471

865781

0.01

50000000

32010375

34310375

32010375

34310375

277353

565630

1227247

266060

964937

-3750

2868275

551220

2340055

-23000

89503

163719

700977

2038919

187850

401911

526270

829356

114774 200164 475056 715511

26314

61822

125359

194674

63932

149261

79487

177899

205020

411247

679902

1088084

-17170

-9336

-153632

-258728

8158

18626

2750

5813

-25328

-27962

-156382

-264541

-4300

-8600

-21028

-19362

-156382

-264541

-262025

-2516

43594

-2516

-21028

-19362

-199976

-356049

199668

-262025

-395043

130503

0.00

-0.01

30650000

30204973

32338946

32174661

30650000

30204973

32338946

32174661

32010375

34310375

77733 77733 77733

230000

23000

207000

230000

2300000

40829

79130

28487

4000

40829

38867

118562

40829

77733

230000

120355

296638

-19529

118204

39868

254159

-56433

-76662

79130

130000

58714

-10800

60486

79130

4053

2468

18626

5813

<table style="font: 10pt/normal times new roman, times, serif; width: 100%; font-size-adjust: none; font-stretch: normal;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top; font: 10pt times new roman, times, serif;"> <td style="width: 36px; text-align: justify; font: 10pt times new roman, times, serif;">1.</td> <td style="text-align: justify; font: 10pt times new roman, times, serif;">Organization and Going Concern</td> </tr> </table>   Immudyne, Inc. (the “Company”) is a Delaware corporation established to develop, manufacture and sell natural immune support products containing the Company’s proprietary yeast beta glucans, a group of beta glucans naturally occurring in the cell walls of yeast that have been shown through testing and analysis to support the immune system. The Company’s products include once a day oral intake tablets and topical creams and gels for skin application. The Company concentrates its sales and marketing efforts on healthcare professionals, distributors for its all-natural raw material ingredient products and direct-to-consumer sales.   In 2015, the Company formed a joint venture domiciled in Puerto Rico, Innate Skincare, LLC d/b/a Innate Scientific, LLC (“Innate”).  Under the terms of the joint venture agreement, the Company held a 33.3% equity interest, and a 51% controlling voting interest, in Innate. On January 20, 2016, Innate amended its limited liability company operating agreement and changed its legal name to Immudyne PR LLC (“Immudyne PR”). On April 1, 2016, Immudyne PR further amended its operating agreement and restated the Company’s ownership and voting interest in Immudyne PR increased to 78.16667%. Immudyne PR was formed to launch a complete skin care regime formulated using strategic ingredients provided by the Company. Immudyne PR is also currently pursuing other opportunities.   The Company has funded operations in the past through the sales of its products, issuance of common stock and through loans and advances from officers and directors. The Company’s continued operations are dependent upon obtaining an increase in its sales volume and the continued financial support from officers and directors or the issuance of additional shares of common stock.   The accompanying financial statements have been prepared on the basis that the Company will continue as a going concern, which assumes the realization of assets and the satisfaction of liabilities in the normal course of business. At June 30, 2016, the Company has an accumulated deficit approximating $8.8 million and has incurred negative cash flows from operations. These conditions raise substantial doubt about the Company's ability to continue as a going concern. The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty.   Based on the Company's cash balance at June 30, 2016, and projected cash needs for the remainder of 2016, management estimates that it will need to increase sales revenue and/or raise additional capital to cover operating and capital requirements for the 2016 year. Management plans on raising the additional needed funds through increased sales volume, issuing additional shares of common stock or other equity securities, or obtaining debt financing. Although management has been successful to date in raising necessary funding, there can be no assurance that sales revenue will substantially increase or that any required future financing can be successfully completed on a timely basis, or on terms acceptable to the Company.

<table style="font: 10pt/normal times new roman, times, serif; width: 100%; font-size-adjust: none; font-stretch: normal;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top; font: 10pt times new roman, times, serif;"> <td style="width: 36px; text-align: justify; font: 10pt times new roman, times, serif;">2.</td> <td style="text-align: justify; font: 10pt times new roman, times, serif;">Summary of Significant Accounting Policies</td> </tr> </table>   Unaudited Financial Statements   The accompanying unaudited financial statements have been prepared in accordance with generally accepted accounting principles for financial information and with the instructions to Form 10-Q. They do not include all information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. The unaudited financial statements should be read in conjunction with those financial statements included in the Company’s previously filed Form 10-K for the year ended December 31, 2015. In the opinion of management, all adjustments considered necessary for a fair presentation, consisting solely of normal recurring adjustments, have been made. Operating results for the six months ended June 30, 2016 are not necessarily indicative of the results that may be expected for the year ending December 31, 2016.   Basis of Presentation and Use of Estimates   The consolidated financial statements include the accounts of the Company and its controlled subsidiary, Immudyne PR. The non- controlling interest in Immudyne PR represents the 21.833% equity interest held by other members of the joint venture. All intercompany transactions have been eliminated.   The Company prepares its consolidated financial statements in conformity with accounting principles generally accepted in the United States of America which requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Some of the more significant estimates required to be made by management include the valuation of inventory and stockholders’ equity based transactions. Actual results could differ from those estimates.   Inventory   At June 30, 2016 and December 31, 2015, inventory consisted primarily of cosmetic and nutraceutical additives, and finished cosmetic products. Inventory is maintained in the Company’s leased Kentucky warehouse and third party warehouses in Nevada and Louisiana.    Inventory is valued at the lower of cost or market with cost determined on a first-in, first-out (“FIFO”) basis. Management compares the cost of inventory with the net realizable value and an allowance is made for writing down inventory to market value, if lower. At June 30, 2016 and December 31, 2015 the Company recorded an inventory reserve in the amount of $20,000. Inventory consists of the following:   <table style="font: 10pt/normal times new roman, times, serif; width: 100%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="background-color: white;"> </td> <td> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center;" colspan="2">June 30, 2016</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center;" colspan="2">December 31, 2015</td> <td style="padding-bottom: 1.5pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="background-color: white;"> </td> <td> </td> <td> </td> <td style="text-align: right;" colspan="2"> </td> <td> </td> <td> </td> <td style="text-align: right;" colspan="2"> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="width: 36px; background-color: white;"> </td> <td style="text-align: left;">Raw materials</td> <td style="width: 1%;"> </td> <td style="width: 1%; text-align: left;">$</td> <td style="width: 8%; text-align: right;">56,957</td> <td style="width: 1%; text-align: left;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%; text-align: left;">$</td> <td style="width: 8%; text-align: right;">25,761</td> <td style="width: 1%; text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="background-color: white;"> </td> <td style="padding-bottom: 1.5pt; text-align: left;">Finished products</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: left;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right;">122,298</td> <td style="padding-bottom: 1.5pt; text-align: left;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: left;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right;">35,290</td> <td style="padding-bottom: 1.5pt; text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="background-color: white;"> </td> <td style="padding-bottom: 4pt;"> </td> <td style="padding-bottom: 4pt;"> </td> <td style="border-bottom: black 4pt double; text-align: left;">$</td> <td style="border-bottom: black 4pt double; text-align: right;">179,255</td> <td style="padding-bottom: 4pt; text-align: left;"> </td> <td style="padding-bottom: 4pt;"> </td> <td style="border-bottom: black 4pt double; text-align: left;">$</td> <td style="border-bottom: black 4pt double; text-align: right;">61,051</td> <td style="padding-bottom: 4pt; text-align: left;"> </td> </tr> </table>   Revenue Recognition   The Company’s policy is to record revenue as earned when a firm commitment, indicating sales quantity and price exists, delivery has taken place and collectability is reasonably assured. The Company generally records sales of nutraceutical and cosmetic additives once the product is shipped to the customer, and for sales of finished cosmetic products once the customer places the order and the product is simultaneously shipped. Provisions for discounts, returns, allowances, customer rebates and other adjustments are netted with gross sales. The Company accounts for such provisions during the same period in which the related revenues are earned. Customer discounts, returns and rebates approximated $620,000 and $1,050,000 in the three-month and six-month periods ended June 30, 2016, respectively. Customer discounts, returns and rebates were not significant in the three-month and six-month periods ended June 30, 2015.   Delivery is considered to have occurred when title and risk of loss have transferred to the customer. If title does not pass until the product reaches the customer’s delivery site or the customer accepts the product, then recognition of revenue is deferred until that time. There are no formal sales incentives offered to any of the Company’s customers. Volume discounts may be offered from time to time to customers purchasing large quantities on a per transaction basis.   Revenue for the six-month period ended June 30, 2016 consisted of nutraceutical and cosmetic additives ($528,220) and finished cosmetic products ($2,340,055). Revenue for the six month period ended June 30, 2015 consisted solely of nutraceutical and cosmetic additives. Revenue for the three-month period ended June 30, 2016 consisted of nutraceutical and cosmetic additives ($262,310) and finished cosmetic products ($964,937). Revenue for the three month period ended June 30, 2015 consisted solely of nutraceutical and cosmetic additives.   Accounts receivable   Accounts receivable are carried at original invoice amount less an estimate made for holdbacks and doubtful receivables based on a review of all outstanding amounts. Management determines the allowance for doubtful accounts by regularly evaluating individual customer receivables and considering a customer’s financial condition, credit history and current economic conditions and sets up an allowance for doubtful accounts when collection is uncertain. Customers’ accounts are written off when all attempts to collect have been exhausted. Recoveries of accounts receivable previously written off are recorded as income when received. At June 30, 2016 and December 31, 2015 the accounts receivable reserve was approximately $87,000 and $18,000, respectively.   Segments   The guidance for disclosures about segments of an enterprise requires that a public business enterprise report financial and descriptive information about its operating segments. Generally, financial information is required to be reported on the basis used internally for evaluating segment performance and resource allocation. The Company manages its operations in two reportable segments for purposes of assessing performance and making operating decisions. Revenue is generated predominately in the United States, and all significant assets are held in the United States, or United States territories.   A summary of the company’s reportable segments is as follows:   <table style="font: 10pt/normal times new roman, times, serif; width: 100%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="background-color: white;"> </td> <td style="font-weight: bold; padding-bottom: 1.5pt;">Total assets:</td> <td style="padding-bottom: 1.5pt;"> </td> <td colspan="2"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td colspan="2"> </td> <td style="padding-bottom: 1.5pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="background-color: white;"> </td> <td style="font-weight: bold; padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td colspan="2"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td colspan="2"> </td> <td style="padding-bottom: 1.5pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="background-color: white;"> </td> <td> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center;" colspan="2">June 30, 2016</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center;" colspan="2">December 31, 2015</td> <td style="padding-bottom: 1.5pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="width: 36px; background-color: white;"> </td> <td style="text-align: left;">Nutraceutical and Cosmetic Additives</td> <td style="width: 1%;"> </td> <td style="width: 1%; text-align: left;">$</td> <td style="width: 8%; text-align: right;">417,818</td> <td style="width: 1%; text-align: left;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%; text-align: left;">$</td> <td style="width: 8%; text-align: right;">412,324</td> <td style="width: 1%; text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="background-color: white;"> </td> <td style="text-align: left;">Finished Cosmetic Products</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">562,717</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">101,828</td> <td style="text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="background-color: white;"> </td> <td style="padding-bottom: 1.5pt;">Eliminations</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: left;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right;">(114,754</td> <td style="padding-bottom: 1.5pt; text-align: left;">)</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: left;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right;">(65,681</td> <td style="padding-bottom: 1.5pt; text-align: left;">)</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="background-color: white;"> </td> <td style="font-weight: bold; padding-bottom: 4pt;">Total</td> <td style="font-weight: bold; padding-bottom: 4pt;"> </td> <td style="border-bottom: black 4pt double; font-weight: bold; text-align: left;">$</td> <td style="border-bottom: black 4pt double; font-weight: bold; text-align: right;">865,781</td> <td style="font-weight: bold; padding-bottom: 4pt; text-align: left;"> </td> <td style="font-weight: bold; padding-bottom: 4pt;"> </td> <td style="border-bottom: black 4pt double; font-weight: bold; text-align: left;">$</td> <td style="border-bottom: black 4pt double; font-weight: bold; text-align: right;">448,471</td> <td style="font-weight: bold; padding-bottom: 4pt; text-align: left;"> </td> </tr> </table>   <table style="font: 10pt/normal times new roman, times, serif; width: 100%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="background-color: white;"> </td> <td style="font-weight: bold; padding-bottom: 1.5pt;">Total sales:</td> <td style="padding-bottom: 1.5pt;"> </td> <td colspan="2"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td colspan="2"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td colspan="2"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td colspan="2"> </td> <td style="padding-bottom: 1.5pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="background-color: white;"> </td> <td style="font-weight: bold; padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td colspan="2"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td colspan="2"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td colspan="2"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td colspan="2"> </td> <td style="padding-bottom: 1.5pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="background-color: white;"> </td> <td> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center;" colspan="6">Three months ended</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center;" colspan="6">Six months ended</td> <td style="padding-bottom: 1.5pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="background-color: white;"> </td> <td> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center;" colspan="2">June 30, 2016</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center;" colspan="2">June 30, 2015</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center;" colspan="2">June 30, 2016</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center;" colspan="2">June 30, 2015</td> <td style="padding-bottom: 1.5pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="width: 36px; background-color: white;"> </td> <td style="text-align: left;">Nutraceutical and Cosmetic Additives</td> <td style="width: 1%;"> </td> <td style="width: 1%; text-align: left;">$</td> <td style="width: 8%; text-align: right;">266,060</td> <td style="width: 1%; text-align: left;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%; text-align: left;">$</td> <td style="width: 8%; text-align: right;">277,353</td> <td style="width: 1%; text-align: left;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%; text-align: left;">$</td> <td style="width: 8%; text-align: right;">551,220</td> <td style="width: 1%; text-align: left;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%; text-align: left;">$</td> <td style="width: 8%; text-align: right;">565,630</td> <td style="width: 1%; text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="background-color: white;"> </td> <td style="text-align: left;">Finished Cosmetic Products</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">964,937</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">-</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">2,340,055</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">-</td> <td style="text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="background-color: white;"> </td> <td style="padding-bottom: 1.5pt;">Eliminations</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: left;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right;">(3,750</td> <td style="padding-bottom: 1.5pt; text-align: left;">)</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: left;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right;">-</td> <td style="padding-bottom: 1.5pt; text-align: left;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: left;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right;">(23,000</td> <td style="padding-bottom: 1.5pt; text-align: left;">)</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: left;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right;">-</td> <td style="padding-bottom: 1.5pt; text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="background-color: white;"> </td> <td style="font-weight: bold; padding-bottom: 4pt;">Total</td> <td style="font-weight: bold; padding-bottom: 4pt;"> </td> <td style="border-bottom: black 4pt double; font-weight: bold; text-align: left;">$</td> <td style="border-bottom: black 4pt double; font-weight: bold; text-align: right;">1,227,247</td> <td style="font-weight: bold; padding-bottom: 4pt; text-align: left;"> </td> <td style="font-weight: bold; padding-bottom: 4pt;"> </td> <td style="border-bottom: black 4pt double; font-weight: bold; text-align: left;">$</td> <td style="border-bottom: black 4pt double; font-weight: bold; text-align: right;">277,353</td> <td style="font-weight: bold; padding-bottom: 4pt; text-align: left;"> </td> <td style="font-weight: bold; padding-bottom: 4pt;"> </td> <td style="border-bottom: black 4pt double; font-weight: bold; text-align: left;">$</td> <td style="border-bottom: black 4pt double; font-weight: bold; text-align: right;">2,868,275</td> <td style="font-weight: bold; padding-bottom: 4pt; text-align: left;"> </td> <td style="font-weight: bold; padding-bottom: 4pt;"> </td> <td style="border-bottom: black 4pt double; font-weight: bold; text-align: left;">$</td> <td style="border-bottom: black 4pt double; font-weight: bold; text-align: right;">565,630</td> <td style="font-weight: bold; padding-bottom: 4pt; text-align: left;"> </td> </tr> </table>   <table style="font: 10pt/normal times new roman, times, serif; width: 100%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="background-color: white;"> </td> <td style="font-weight: bold; padding-bottom: 1.5pt;">Net (loss) income:</td> <td style="padding-bottom: 1.5pt;"> </td> <td colspan="2"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td colspan="2"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td colspan="2"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td colspan="2"> </td> <td style="padding-bottom: 1.5pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="background-color: white;"> </td> <td style="font-weight: bold; padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td colspan="2"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td colspan="2"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td colspan="2"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td colspan="2"> </td> <td style="padding-bottom: 1.5pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="background-color: white;"> </td> <td> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center;" colspan="6">Three months ended</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center;" colspan="6">Six months ended</td> <td style="padding-bottom: 1.5pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="background-color: white;"> </td> <td> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center;" colspan="2">June 30, 2016</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center;" colspan="2">June 30, 2015</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center;" colspan="2">June 30, 2016</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center;" colspan="2">June 30, 2015</td> <td style="padding-bottom: 1.5pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="width: 36px; background-color: white;"> </td> <td style="text-align: left;">Nutraceutical and Cosmetic Additives</td> <td style="width: 1%;"> </td> <td style="width: 1%; text-align: left;">$</td> <td style="width: 8%; text-align: right;">(356,049</td> <td style="width: 1%; text-align: left;">)</td> <td style="width: 1%;"> </td> <td style="width: 1%; text-align: left;">$</td> <td style="width: 8%; text-align: right;">(21,028</td> <td style="width: 1%; text-align: left;">)</td> <td style="width: 1%;"> </td> <td style="width: 1%; text-align: left;">$</td> <td style="width: 8%; text-align: right;">(395,043</td> <td style="width: 1%; text-align: left;">)</td> <td style="width: 1%;"> </td> <td style="width: 1%; text-align: left;">$</td> <td style="width: 8%; text-align: right;">(19,362</td> <td style="width: 1%; text-align: left;">)</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="background-color: white;"> </td> <td style="text-align: left;">Finished Cosmetic Products</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">199,668</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">-</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">130,503</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">-</td> <td style="text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="background-color: white;"> </td> <td style="padding-bottom: 1.5pt;">Eliminations</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: left;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right;">-</td> <td style="padding-bottom: 1.5pt; text-align: left;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: left;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right;">-</td> <td style="padding-bottom: 1.5pt; text-align: left;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: left;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right;">-</td> <td style="padding-bottom: 1.5pt; text-align: left;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: left;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right;">-</td> <td style="padding-bottom: 1.5pt; text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="background-color: white;"> </td> <td style="font-weight: bold; padding-bottom: 4pt;">Total</td> <td style="font-weight: bold; padding-bottom: 4pt;"> </td> <td style="border-bottom: black 4pt double; font-weight: bold; text-align: left;">$</td> <td style="border-bottom: black 4pt double; font-weight: bold; text-align: right;">(156,381</td> <td style="font-weight: bold; padding-bottom: 4pt; text-align: left;">)</td> <td style="font-weight: bold; padding-bottom: 4pt;"> </td> <td style="border-bottom: black 4pt double; font-weight: bold; text-align: left;">$</td> <td style="border-bottom: black 4pt double; font-weight: bold; text-align: right;">(21,028</td> <td style="font-weight: bold; padding-bottom: 4pt; text-align: left;">)</td> <td style="font-weight: bold; padding-bottom: 4pt;"> </td> <td style="border-bottom: black 4pt double; font-weight: bold; text-align: left;">$</td> <td style="border-bottom: black 4pt double; font-weight: bold; text-align: right;">(264,540</td> <td style="font-weight: bold; padding-bottom: 4pt; text-align: left;">)</td> <td style="font-weight: bold; padding-bottom: 4pt;"> </td> <td style="border-bottom: black 4pt double; font-weight: bold; text-align: left;">$</td> <td style="border-bottom: black 4pt double; font-weight: bold; text-align: right;">(19,362</td> <td style="font-weight: bold; padding-bottom: 4pt; text-align: left;">)</td> </tr> </table>   As of and for the six months ended June 30, 2015, there were no assets, sales or net loss relative to the finished cosmetic products segment.    Income Taxes   The Company files Corporate Federal and State tax returns, while Innate, which was formed as a limited liability corporation, files a separate tax return with any tax liabilities or benefits passing through to its members.   The Company records current and deferred taxes in accordance with Accounting Standards Codification (ASC) 740, “Accounting for Income Taxes.” This ASC requires recognition of deferred tax assets and liabilities for temporary differences between tax basis of assets and liabilities and the amounts at which they are carried in the financial statements, based upon the enacted rates in effect for the year in which the differences are expected to reverse. The Company establishes a valuation allowance when necessary to reduce deferred tax assets to the amount expected to be realized. The Company periodically assesses the value of its deferred tax asset, a majority of which has been generated by a history of net operating losses and determines the necessity for a valuation allowance. ASC 740 also provides a recognition threshold and measurement attribute for the financial statement recognition of a tax position taken or expected to be taken in a tax return. Using this guidance, a company may recognize the tax benefit from an uncertain tax position in its financial statements only if it is more likely-than-not (i.e., a likelihood of more than 50%) that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position.   The Company’s tax returns for all years since December 31, 2012, remain open to taxing authorities.   Stock-Based Compensation   The Company follows the provisions of ASC 718, “Share-Based Payment”. Under this guidance compensation cost generally is recognized at fair value on the date of the grant and amortized over the respective vesting periods. The fair value of options at the date of grant is estimated using the Black-Scholes option pricing model. The expected option life is derived from assumed exercise rates based upon historical exercise patterns and represents the period of time that options granted are expected to be outstanding. The expected volatility is based upon historical volatility of the Company’s shares using weekly price observations over an observation period that approximates the expected life of the options. The risk-free rate approximates the U.S. Treasury yield curve rate in effect at the time of grant for periods similar to the expected option life. Due to limited history of forfeitures, the estimated forfeiture rate included in the option valuation was zero.   Many of the assumptions require significant judgment and any changes could have a material impact in the determination of stock-based compensation expense.    Earnings (Loss) Per Share   Basic earnings (loss) per common share is based on the weighted average number of shares outstanding during each period presented. Warrants and options to purchase common stock are included as common stock equivalents only when dilutive. Potential common stock equivalents are excluded from dilutive earnings per share when the effects would be antidilutive.   Common stock equivalents comprising shares underlying 12,700,273 options and warrants for the three and six months ended June 30, 2016 have not been included in the loss per share calculation as the effects are anti-dilutive. Common stock equivalents comprising shares underlying 12,085,000 options and warrants for the three and six months ended June 30, 2015 have not been included in the loss per share calculations as the effects are anti-dilutive.   Recent Accounting Pronouncements   In March 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-09, “Compensation – Stock Compensation: Improvements to Employee Share-Based Payment Accounting,” which relates to the accounting for employee share-based payments. This standard addresses several aspects of the accounting for share-based payment award transactions, including: (a) income tax consequences; (b) classification flows of awards as either equity or liabilities; and (c) classification on the statement of cash flows. This standard will be effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. The Company is in the process of evaluating the impact of the adoption of ASU 2016-09 on its consolidated financial statements.   In February 2016, a pronouncement was issued that creates new accounting and reporting guidelines for leasing arrangements. The new guidance requires organizations that lease assets to recognize assets and liabilities on the balance sheet related to the rights and obligations created by those leases, regardless of whether they are classified as finance or operating leases. Consistent with current guidance, the recognition, measurement, and presentation of expenses and cash flows arising from a lease primarily will depend on its classification as a finance or operating lease. The guidance also requires new disclosures to help financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. The new standard is effective for annual reporting periods beginning after December 15, 2018, including interim periods within that reporting period, with early application permitted. The new standard is to be applied using a modified retrospective approach. The Company is in the process of evaluating the impact of the new pronouncement on its consolidated financial statements.   In May 2014, the Financial Accounting Standards Board ("FASB") issued accounting guidance, "Revenue from Contracts with Customers." The core principle of the new standard is for companies to recognize revenue to depict the transfer of goods or services to customers in amounts that reflect the consideration (that is, payment) to which the company expects to be entitled in exchange for those goods or services. The new standard also will result in enhanced disclosures about revenue, provide guidance for transactions that were not previously addressed comprehensively (for example, service revenue and contract modifications) and clarify guidance for multiple-element arrangements. The standard will be effective for fiscal years and interim periods within those years beginning after December 15, 2017. Accordingly, the Company will adopt this standard in the first quarter of fiscal year 2018. The Company is currently evaluating the impact this guidance will have on the consolidated financial statements.   In July 2015, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2015-11, “Simplifying the Measurement of Inventory.” ASU 2015-11 applies to inventory that is measured using first-in, first-out (FIFO) or average cost.  An entity should measure inventory within the scope of ASU 2015-11 at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation.  ASU 2015-11 is effective for fiscal years beginning after December 15, 2016. The Company is in the process of evaluating the impact of this ASU on its consolidated financial statements.   In August 2014, the FASB issued ASU 2014-15, "Presentation of Financial Statements-Going Concern". This ASU is intended to define management's responsibility to evaluate whether there is substantial doubt about an organization's ability to continue as a going concern and to provide related footnote disclosures. It is effective for annual periods beginning after December 15, 2016, with early adoption permitted. The Company does not expect it to have a material effect on the Company's consolidated financial condition, results of operations, and cash flows.   All other accounting standards that have been issued or proposed by the FASB that do not require adoption until a future date are not expected to have a material impact on the consolidated financial statements upon adoption.   Fair Value of Financial Instruments   The carrying value of the Company’s financial instruments, including cash, trade accounts receivable and accounts payable and accrued expenses and notes payable approximate fair value for all periods.   Noncontrolling Interests   The Company accounts for its less than 100% interest in Immudyne PR in accordance with ASC Topic 810, Consolidation, and accordingly the Company presents noncontrolling interests as a component of equity on its consolidated balance sheet and reports the noncontrolling interest’s share of the Immudyne PR net loss attributable to noncontrolling interests in the consolidated statement of operations.   Concentration of Credit Risk   The Company grants credit in the normal course of business to its customers. The Company periodically performs credit analysis and monitors the financial condition of its customers to reduce credit risk.   The Company monitors its positions with, and the credit quality of, the financial institutions with which it invests. The Company, at times, maintains balances in various operating accounts in excess of federally insured limits.   One customer in the nutraceutical and cosmetic additives division accounted for 17% and 83% of consolidated sales for each of the three month periods ended June 30, 2016 and 2015, respectively. This customer accounted for 16% and 83% of consolidated sales for the six month periods ended June 30, 2016 and 2015, respectively. This customer accounted for 30% and 43% of accounts receivable at June 30, 2016 and December 31, 2015, respectively.   A second customer in the nutraceutical and cosmetic additives division accounted for 4% and 12% of consolidated sales for each of the three month periods ended June 30, 2016 and 2015, respectively. This customer accounted for 2% and 12% of consolidated sales for the six month periods ended June 30, 2016 and 2015, respectively. This customer accounted for 0% and 24% of accounts receivable at June 30, 2016 and December 31, 2015, respectively.

<table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; width: 36px; text-align: justify; font-stretch: normal;">4.</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-stretch: normal;">Income Taxes</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 27pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 27pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Company is not expected to have taxable income in 2016 and incurred a loss for the year ended December 31, 2015 and accordingly, no provision for federal income tax has been made in the accompanying financial statements. At December 31, 2015, the Company had available net operating loss carryforwards of approximately $2,730,000, expiring during various years through 2035.<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 27pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 27pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">A summary of the deferred tax asset using an approximate 34% tax rate is as follows:<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 27pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"> <table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal; background-color: #cceeff;"><td style="font: 10pt/normal 'times new roman', times, serif; width: 27pt; font-stretch: normal; background-color: white;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0pt; text-align: left; text-indent: 0pt; font-stretch: normal;">Deferred Tax Asset</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0pt; width: 15px; text-indent: 0pt; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0pt; width: 15px; text-align: left; text-indent: 0pt; font-stretch: normal;">$</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0pt; width: 109px; text-align: right; text-indent: 0pt; font-stretch: normal;">930,000</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0pt; width: 15px; text-align: left; text-indent: 0pt; font-stretch: normal;"> </td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal; background-color: white;"><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: white;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0pt; text-align: left; text-indent: 0pt; font-stretch: normal;">Valuation allowance</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0pt; text-indent: 0pt; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0pt; text-align: left; text-indent: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0pt; text-align: right; text-indent: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">(930,000</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0pt; text-align: left; text-indent: 0pt; font-stretch: normal;">)</td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal; background-color: #cceeff;"><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: white;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0pt 0pt 0pt 10pt; text-indent: 0pt; font-stretch: normal;">Total</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0pt; text-indent: 0pt; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0pt; text-align: left; text-indent: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">$</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0pt; text-align: right; text-indent: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">-</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0pt; text-align: left; text-indent: 0pt; font-stretch: normal;"> </td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 27pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 27pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">The net operating loss carryforwards could be subject to limitation in any given year in the event of a change in ownership as defined by IRC Section 382.<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 27pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 27pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">The deferred tax benefit included in the statement of operations represents the change in the deferred tax liability at each balance sheet date.<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 27pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 27pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">The difference between the statutory and the effective tax rate is primarily due to a change in valuation allowance on deferred taxes, as the Company has fully reserved the deferred tax asset resulting from available net operating loss carryforwards.

<table style="font: 10pt/normal times new roman, times, serif; width: 100%; font-size-adjust: none; font-stretch: normal;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top; font: 10pt times new roman, times, serif;"> <td style="width: 36px; text-align: justify; font: 10pt times new roman, times, serif;">5.</td> <td style="text-align: justify; font: 10pt times new roman, times, serif;">Stockholders’ Equity</td> </tr> </table>   On April 1, 2016, the Company entered into two agreements with two consultants to provide services over a nine month period in exchange for 2,300,000 shares of common stock. The Company valued the shares based on the market price on the agreement dates and for the three and six months ended June 30, 2016, the Company has recognized compensation expense of $230,000 in connection with these agreements.   Service-Based Stock Options   In May 2016, the Company issued 175,000 service-based options valued at $40,829 to two consultants at exercise prices of $0.20 per share. The options are fully vested and expire in 10 years. Accordingly, stock based compensation for the three and six months ended June 30, 2016 included $40,829 related to such options.   A Summary of the outstanding service-based options are as follows:   <table style="font: 10pt/normal times new roman, times, serif; width: 100%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="background-color: white;"> </td> <td> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center;" colspan="2">Number of Options</td> <td style="padding-bottom: 1.5pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="width: 36px; background-color: white;"> </td> <td>Balance at December 31, 2015</td> <td style="width: 1%;"> </td> <td style="width: 1%; text-align: left;"> </td> <td style="width: 8%; text-align: right;">11,025,273</td> <td style="width: 1%; text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="background-color: white;"> </td> <td>Cancelled</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(250,000</td> <td style="text-align: left;">)</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="background-color: white;"> </td> <td style="padding-bottom: 1.5pt;">Issued</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: left;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right;">175,000</td> <td style="padding-bottom: 1.5pt; text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="background-color: white;"> </td> <td> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="background-color: white;"> </td> <td style="padding-bottom: 4pt;">Balance at June 30, 2016</td> <td style="padding-bottom: 4pt;"> </td> <td style="border-bottom: black 4pt double; text-align: left;"> </td> <td style="border-bottom: black 4pt double; text-align: right;">10,950,273</td> <td style="padding-bottom: 4pt; text-align: left;"> </td> </tr> </table>   All outstanding options are exercisable and have a cashless exercise provision, and certain options provide for accelerated vesting provisions and modifications, as defined, if the Company is sold or acquired. The intrinsic value of options outstanding and exercisable at June 30, 2016 amounted to $747,294.   The significant assumptions used to determine the fair values of options issued, using a Black-Scholes option-pricing model are as follows:   <table style="font: 10pt/normal times new roman, times, serif; width: 100%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="background-color: white;"> </td> <td style="border-bottom: black 1.5pt solid;">Significant assumptions :</td> <td style="padding-bottom: 1.5pt;"> </td> <td colspan="2"> </td> <td style="padding-bottom: 1.5pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="width: 36px; background-color: white;"> </td> <td style="text-align: left;">Risk-free interest rate at grant date</td> <td style="width: 1%;"> </td> <td style="width: 1%; text-align: left;"> </td> <td style="width: 8%; text-align: right;">1.88</td> <td style="width: 1%; text-align: left;">%</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="background-color: white;"> </td> <td style="text-align: left;">Expected stock price volatility</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">248.4</td> <td style="text-align: left;">%</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="background-color: white;"> </td> <td style="text-align: left;">Expected dividend payout</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">—</td> <td style="text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="background-color: white;"> </td> <td style="text-align: left;">Expected option life-years</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">3</td> <td style="text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="background-color: white;"> </td> <td>Weighted average grant date fair value</td> <td> </td> <td style="text-align: left;">$</td> <td style="text-align: right;">0.24</td> <td style="text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="background-color: white;"> </td> <td style="text-align: left;">Forfeiture rate</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">0</td> <td style="text-align: left;">%</td> </tr> </table>   The following is a summary of outstanding service-based options at June 30, 2016:   <table style="font: 10pt/normal times new roman, times, serif; width: 100%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="background-color: white;"> </td> <td style="border-bottom: black 1.5pt solid;">Exercise Price</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center;" colspan="2">Number of Options</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center;" colspan="2">Weighted Average Remaining Contractual Life</td> <td style="padding-bottom: 1.5pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="background-color: white;"> </td> <td> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: center;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="width: 36px; background-color: white;"> </td> <td style="text-align: left;">$0.10</td> <td style="width: 1%;"> </td> <td style="width: 1%; text-align: left;"> </td> <td style="width: 8%; text-align: right;">1,680,273</td> <td style="width: 1%; text-align: left;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%; text-align: center;"> </td> <td style="width: 8%; text-align: center;">2 years</td> <td style="width: 1%; text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="background-color: white;"> </td> <td style="text-align: left;">$0.20 - $0.25</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">8,120,000</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: center;"> </td> <td style="text-align: center;">6 years</td> <td style="text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="background-color: white;"> </td> <td style="padding-bottom: 1.5pt; text-align: left;">$0.40</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: left;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right;">1,150,000</td> <td style="padding-bottom: 1.5pt; text-align: left;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt; text-align: left;"> </td> <td style="padding-bottom: 1.5pt; text-align: center;">5 years</td> <td style="padding-bottom: 1.5pt; text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="background-color: white;"> </td> <td style="padding-bottom: 4pt; text-align: left; padding-left: 10pt;">Total</td> <td style="padding-bottom: 4pt;"> </td> <td style="border-bottom: black 4pt double; text-align: left;"> </td> <td style="border-bottom: black 4pt double; text-align: right;">10,950,273</td> <td style="padding-bottom: 4pt; text-align: left;"> </td> <td style="padding-bottom: 4pt;"> </td> <td style="padding-bottom: 4pt; text-align: left;"> </td> <td style="padding-bottom: 4pt; text-align: right;"> </td> <td style="padding-bottom: 4pt; text-align: left;"> </td> </tr> </table>   Performance-Based Stock Options   The Company had granted performance-based options to purchase 4,530,000 shares of common stock at exercise prices of $0.40 to $0.80. The options expire at various dates between 2021 and 2025 and are exercisable upon the Company achieving annual sales revenue of $5,000,000 and $10,000,000. The fair value of these performance-based options aggregated $135,567 to be expensed over the implicit service period commencing once management believes the performance criteria will be met.   Management believes the performance criteria for options exercisable upon the Company achieving annual sales revenue of $5,000,000, with a fair value amounting to $116,600, will be met during the year ended December 31, 2016. Accordingly, stock based compensation expense for the three and six months ended June 30, 2016 includes $38,867 and $77,733, respectively, related to such options. At June 30, 2016, the unearned compensation for all the performance based options is $57,834.   Stock based compensation expense amounted to $309,695 and $2,000 for the three month periods ended June 30, 2016 and 2015, respectively. Stock based compensation expense amounted to $348,562 and $4,000 for the six month periods ended June 30, 2016 and 2015, respectively. Such amounts are included in compensation and related expenses in the accompanying statement of operations.   Warrants   Warrants outstanding and exercisable amounted to 1,750,000 at December 31, 2015 and June 30, 2016. The weighted average exercise price of warrants outstanding at June 30, 2016 is $0.16. The warrants expire during November 2016 and December 2017.

<table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"> <tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"> <td style="font: 10pt/normal 'times new roman', times, serif; width: 36px; text-align: justify; font-stretch: normal;">7.</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-stretch: normal;">Commitments and Contingencies</td> </tr> </table> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 108pt; text-align: justify; color: #000000; text-transform: none; text-indent: -81pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 27pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Leases <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 27pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 27pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Company leases a plant in Kentucky under an operating lease which expired on May 31, 2016. Management is currently discussing renewal lease options for the Kentucky plant and is operating on a month-to-month lease arrangement until a final agreement has been accepted. Monthly base rental payments are approximately $9,000. In addition, Immudyne PR operates in Puerto Rico in space owned by one of the parties to the joint venture. Rent expense for the three month periods ended June 30, 2016 and 2015, was $27,284 and $14,468, respectively. Rent expense for the six month periods ended June 30, 2016 and 2015, was $43,900 and $34,929, respectively. <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 27pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 27pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Employment and Consulting Agreements <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 27pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 27pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Company has entered into various agreements with officers, directors, employees and consultants that expire in one to five years. The agreements provide for annual compensation of up to $145,000 and the issuance of stock options, at exercise prices of $0.40 and $0.80, to purchase 4,530,000 shares of common stock issuable upon the Company’s revenue exceeding $5,000,000 and $10,000,000, as defined. In addition, the agreements provide for bonus compensation to these individuals aggregating up to 15% (with no individual having more than 5%) of the Company’s pretax income. <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 27pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 27pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Restricted Stock and Options <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 27pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 27pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Company has entered into two agreements on April 1, 2016 with two consultants of Immudyne PR for business development, marketing and sales related services (the “Consultant Agreements”). Upon signing, each consultant was issued 1,000,000 restricted shares of Immudyne, Inc. common stock. In addition, each consultant shall receive an additional 150,000 restricted shares of Immudyne, Inc. common stock for each $500,000 distributed by Immudyne PR to the Company. For each consultant the amount of shares to be issued by the Company to the consultants shall be capped at 1,500,000 restricted shares when Immudyne PR has transferred $5,000,000 to the Company, for a combined capped total of 3,000,000 restricted shares. For the three and six months ended June 30, 2016, 2,300,000 restricted shares of common stock have been issued related to these agreements. <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 27pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 27pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">In addition, the Consulting Agreements provided that each consultant shall receive a bonus of an additional 750,000 restricted shares of Immudyne Inc. common stock, plus an option to buy 1,000,000 shares of Immudyne, Inc. common stock at $0.20/share (including a cashless exercise feature) when Immudyne PR has transferred to the Company at each of the following three (3) thresholds: $1,250,000, $2,000,000 and $3,000,000 for a total of 2,250,000 of restricted shares of Immudyne, Inc. common stock and options to purchase up to 3,000,000 shares of Immudyne, Inc. common stock at $0.20/share. As of June 30, 2016, no bonus shares have been issued and no options have been granted under this agreement.  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 27pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 27pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Legal Matters <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 27pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 27pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">In the normal course of business operations the Company may become involved in various legal matters. At June 30, 2016, the Company’s management does not believe that there are any potential legal matters that could have an adverse effect on the Company’s financial position.

<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 27pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Inventory<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 27pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 27pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">At June 30, 2016 and December 31, 2015, inventory consisted primarily of cosmetic and nutraceutical additives, and finished cosmetic products. Inventory is maintained in the Company’s leased Kentucky warehouse and third party warehouses in Nevada and Louisiana.<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 27pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Inventory is valued at the lower of cost or market with cost determined on a first-in, first-out (“FIFO”) basis. Management compares the cost of inventory with the net realizable value and an allowance is made for writing down inventory to market value, if lower. At June 30, 2016 and December 31, 2015 the Company recorded an inventory reserve in the amount of $20,000. Inventory consists of the following:<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 27pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"> <table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: white;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">June 30, 2016</td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">December 31,  2015</td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"> </td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: white;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;" colspan="2"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;" colspan="2"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal; background-color: #cceeff;"><td style="font: 10pt/normal 'times new roman', times, serif; width: 27pt; font-stretch: normal; background-color: white;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">Raw materials</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;">$</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 125px; text-align: right; font-stretch: normal;">56,957</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;">$</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 125px; text-align: right; font-stretch: normal;">25,761</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;"> </td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal; background-color: white;"><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: white;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;">Finished products</td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">122,298</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">35,290</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;"> </td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal; background-color: #cceeff;"><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: white;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">$</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">179,255</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">$</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">61,051</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;"> </td></tr></table>

Revenue Recognition   The Company’s policy is to record revenue as earned when a firm commitment, indicating sales quantity and price exists, delivery has taken place and collectability is reasonably assured. The Company generally records sales of nutraceutical and cosmetic additives once the product is shipped to the customer, and for sales of finished cosmetic products once the customer places the order and the product is simultaneously shipped. Provisions for discounts, returns, allowances, customer rebates and other adjustments are netted with gross sales. The Company accounts for such provisions during the same period in which the related revenues are earned. Customer discounts, returns and rebates approximated $620,000 and $1,050,000 in the three-month and six-month periods ended June 30, 2016, respectively. Customer discounts, returns and rebates were not significant in the three-month and six-month periods ended June 30, 2015.   Delivery is considered to have occurred when title and risk of loss have transferred to the customer. If title does not pass until the product reaches the customer’s delivery site or the customer accepts the product, then recognition of revenue is deferred until that time. There are no formal sales incentives offered to any of the Company’s customers. Volume discounts may be offered from time to time to customers purchasing large quantities on a per transaction basis.   Revenue for the six-month period ended June 30, 2016 consisted of nutraceutical and cosmetic additives ($528,220) and finished cosmetic products ($2,340,055). Revenue for the six month period ended June 30, 2015 consisted solely of nutraceutical and cosmetic additives. Revenue for the three-month period ended June 30, 2016 consisted of nutraceutical and cosmetic additives ($262,310) and finished cosmetic products ($964,937). Revenue for the three month period ended June 30, 2015 consisted solely of nutraceutical and cosmetic additives.

Segments   The guidance for disclosures about segments of an enterprise requires that a public business enterprise report financial and descriptive information about its operating segments. Generally, financial information is required to be reported on the basis used internally for evaluating segment performance and resource allocation. The Company manages its operations in two reportable segments for purposes of assessing performance and making operating decisions. Revenue is generated predominately in the United States, and all significant assets are held in the United States, or United States territories.   A summary of the company’s reportable segments is as follows:   <table style="font: 10pt/normal times new roman, times, serif; width: 100%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="background-color: white;"> </td> <td style="font-weight: bold; padding-bottom: 1.5pt;">Total assets:</td> <td style="padding-bottom: 1.5pt;"> </td> <td colspan="2"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td colspan="2"> </td> <td style="padding-bottom: 1.5pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="background-color: white;"> </td> <td style="font-weight: bold; padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td colspan="2"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td colspan="2"> </td> <td style="padding-bottom: 1.5pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="background-color: white;"> </td> <td> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center;" colspan="2">June 30, 2016</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center;" colspan="2">December 31, 2015</td> <td style="padding-bottom: 1.5pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="width: 36px; background-color: white;"> </td> <td style="text-align: left;">Nutraceutical and Cosmetic Additives</td> <td style="width: 1%;"> </td> <td style="width: 1%; text-align: left;">$</td> <td style="width: 8%; text-align: right;">417,818</td> <td style="width: 1%; text-align: left;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%; text-align: left;">$</td> <td style="width: 8%; text-align: right;">412,324</td> <td style="width: 1%; text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="background-color: white;"> </td> <td style="text-align: left;">Finished Cosmetic Products</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">562,717</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">101,828</td> <td style="text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="background-color: white;"> </td> <td style="padding-bottom: 1.5pt;">Eliminations</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: left;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right;">(114,754</td> <td style="padding-bottom: 1.5pt; text-align: left;">)</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: left;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right;">(65,681</td> <td style="padding-bottom: 1.5pt; text-align: left;">)</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="background-color: white;"> </td> <td style="font-weight: bold; padding-bottom: 4pt;">Total</td> <td style="font-weight: bold; padding-bottom: 4pt;"> </td> <td style="border-bottom: black 4pt double; font-weight: bold; text-align: left;">$</td> <td style="border-bottom: black 4pt double; font-weight: bold; text-align: right;">865,781</td> <td style="font-weight: bold; padding-bottom: 4pt; text-align: left;"> </td> <td style="font-weight: bold; padding-bottom: 4pt;"> </td> <td style="border-bottom: black 4pt double; font-weight: bold; text-align: left;">$</td> <td style="border-bottom: black 4pt double; font-weight: bold; text-align: right;">448,471</td> <td style="font-weight: bold; padding-bottom: 4pt; text-align: left;"> </td> </tr> </table>   <table style="font: 10pt/normal times new roman, times, serif; width: 100%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="background-color: white;"> </td> <td style="font-weight: bold; padding-bottom: 1.5pt;">Total sales:</td> <td style="padding-bottom: 1.5pt;"> </td> <td colspan="2"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td colspan="2"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td colspan="2"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td colspan="2"> </td> <td style="padding-bottom: 1.5pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="background-color: white;"> </td> <td style="font-weight: bold; padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td colspan="2"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td colspan="2"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td colspan="2"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td colspan="2"> </td> <td style="padding-bottom: 1.5pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="background-color: white;"> </td> <td> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center;" colspan="6">Three months ended</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center;" colspan="6">Six months ended</td> <td style="padding-bottom: 1.5pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="background-color: white;"> </td> <td> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center;" colspan="2">June 30, 2016</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center;" colspan="2">June 30, 2015</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center;" colspan="2">June 30, 2016</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center;" colspan="2">June 30, 2015</td> <td style="padding-bottom: 1.5pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="width: 36px; background-color: white;"> </td> <td style="text-align: left;">Nutraceutical and Cosmetic Additives</td> <td style="width: 1%;"> </td> <td style="width: 1%; text-align: left;">$</td> <td style="width: 8%; text-align: right;">266,060</td> <td style="width: 1%; text-align: left;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%; text-align: left;">$</td> <td style="width: 8%; text-align: right;">277,353</td> <td style="width: 1%; text-align: left;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%; text-align: left;">$</td> <td style="width: 8%; text-align: right;">551,220</td> <td style="width: 1%; text-align: left;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%; text-align: left;">$</td> <td style="width: 8%; text-align: right;">565,630</td> <td style="width: 1%; text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="background-color: white;"> </td> <td style="text-align: left;">Finished Cosmetic Products</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">964,937</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">-</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">2,340,055</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">-</td> <td style="text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="background-color: white;"> </td> <td style="padding-bottom: 1.5pt;">Eliminations</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: left;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right;">(3,750</td> <td style="padding-bottom: 1.5pt; text-align: left;">)</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: left;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right;">-</td> <td style="padding-bottom: 1.5pt; text-align: left;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: left;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right;">(23,000</td> <td style="padding-bottom: 1.5pt; text-align: left;">)</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: left;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right;">-</td> <td style="padding-bottom: 1.5pt; text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="background-color: white;"> </td> <td style="font-weight: bold; padding-bottom: 4pt;">Total</td> <td style="font-weight: bold; padding-bottom: 4pt;"> </td> <td style="border-bottom: black 4pt double; font-weight: bold; text-align: left;">$</td> <td style="border-bottom: black 4pt double; font-weight: bold; text-align: right;">1,227,247</td> <td style="font-weight: bold; padding-bottom: 4pt; text-align: left;"> </td> <td style="font-weight: bold; padding-bottom: 4pt;"> </td> <td style="border-bottom: black 4pt double; font-weight: bold; text-align: left;">$</td> <td style="border-bottom: black 4pt double; font-weight: bold; text-align: right;">277,353</td> <td style="font-weight: bold; padding-bottom: 4pt; text-align: left;"> </td> <td style="font-weight: bold; padding-bottom: 4pt;"> </td> <td style="border-bottom: black 4pt double; font-weight: bold; text-align: left;">$</td> <td style="border-bottom: black 4pt double; font-weight: bold; text-align: right;">2,868,275</td> <td style="font-weight: bold; padding-bottom: 4pt; text-align: left;"> </td> <td style="font-weight: bold; padding-bottom: 4pt;"> </td> <td style="border-bottom: black 4pt double; font-weight: bold; text-align: left;">$</td> <td style="border-bottom: black 4pt double; font-weight: bold; text-align: right;">565,630</td> <td style="font-weight: bold; padding-bottom: 4pt; text-align: left;"> </td> </tr> </table>   <table style="font: 10pt/normal times new roman, times, serif; width: 100%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="background-color: white;"> </td> <td style="font-weight: bold; padding-bottom: 1.5pt;">Net (loss) income:</td> <td style="padding-bottom: 1.5pt;"> </td> <td colspan="2"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td colspan="2"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td colspan="2"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td colspan="2"> </td> <td style="padding-bottom: 1.5pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="background-color: white;"> </td> <td style="font-weight: bold; padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td colspan="2"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td colspan="2"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td colspan="2"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td colspan="2"> </td> <td style="padding-bottom: 1.5pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="background-color: white;"> </td> <td> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center;" colspan="6">Three months ended</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center;" colspan="6">Six months ended</td> <td style="padding-bottom: 1.5pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="background-color: white;"> </td> <td> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center;" colspan="2">June 30, 2016</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center;" colspan="2">June 30, 2015</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center;" colspan="2">June 30, 2016</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center;" colspan="2">June 30, 2015</td> <td style="padding-bottom: 1.5pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="width: 36px; background-color: white;"> </td> <td style="text-align: left;">Nutraceutical and Cosmetic Additives</td> <td style="width: 1%;"> </td> <td style="width: 1%; text-align: left;">$</td> <td style="width: 8%; text-align: right;">(356,049</td> <td style="width: 1%; text-align: left;">)</td> <td style="width: 1%;"> </td> <td style="width: 1%; text-align: left;">$</td> <td style="width: 8%; text-align: right;">(21,028</td> <td style="width: 1%; text-align: left;">)</td> <td style="width: 1%;"> </td> <td style="width: 1%; text-align: left;">$</td> <td style="width: 8%; text-align: right;">(395,043</td> <td style="width: 1%; text-align: left;">)</td> <td style="width: 1%;"> </td> <td style="width: 1%; text-align: left;">$</td> <td style="width: 8%; text-align: right;">(19,362</td> <td style="width: 1%; text-align: left;">)</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="background-color: white;"> </td> <td style="text-align: left;">Finished Cosmetic Products</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">199,668</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">-</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">130,503</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">-</td> <td style="text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="background-color: white;"> </td> <td style="padding-bottom: 1.5pt;">Eliminations</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: left;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right;">-</td> <td style="padding-bottom: 1.5pt; text-align: left;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: left;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right;">-</td> <td style="padding-bottom: 1.5pt; text-align: left;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: left;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right;">-</td> <td style="padding-bottom: 1.5pt; text-align: left;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: left;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right;">-</td> <td style="padding-bottom: 1.5pt; text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="background-color: white;"> </td> <td style="font-weight: bold; padding-bottom: 4pt;">Total</td> <td style="font-weight: bold; padding-bottom: 4pt;"> </td> <td style="border-bottom: black 4pt double; font-weight: bold; text-align: left;">$</td> <td style="border-bottom: black 4pt double; font-weight: bold; text-align: right;">(156,381</td> <td style="font-weight: bold; padding-bottom: 4pt; text-align: left;">)</td> <td style="font-weight: bold; padding-bottom: 4pt;"> </td> <td style="border-bottom: black 4pt double; font-weight: bold; text-align: left;">$</td> <td style="border-bottom: black 4pt double; font-weight: bold; text-align: right;">(21,028</td> <td style="font-weight: bold; padding-bottom: 4pt; text-align: left;">)</td> <td style="font-weight: bold; padding-bottom: 4pt;"> </td> <td style="border-bottom: black 4pt double; font-weight: bold; text-align: left;">$</td> <td style="border-bottom: black 4pt double; font-weight: bold; text-align: right;">(264,540</td> <td style="font-weight: bold; padding-bottom: 4pt; text-align: left;">)</td> <td style="font-weight: bold; padding-bottom: 4pt;"> </td> <td style="border-bottom: black 4pt double; font-weight: bold; text-align: left;">$</td> <td style="border-bottom: black 4pt double; font-weight: bold; text-align: right;">(19,362</td> <td style="font-weight: bold; padding-bottom: 4pt; text-align: left;">)</td> </tr> </table>   As of and for the six months ended June 30, 2015, there were no assets, sales or net loss relative to the finished cosmetic products segment.

Earnings (Loss) Per Share   Basic earnings (loss) per common share is based on the weighted average number of shares outstanding during each period presented. Warrants and options to purchase common stock are included as common stock equivalents only when dilutive. Potential common stock equivalents are excluded from dilutive earnings per share when the effects would be antidilutive.   Common stock equivalents comprising shares underlying 12,700,273 options and warrants for the three and six months ended June 30, 2016 have not been included in the loss per share calculation as the effects are anti-dilutive. Common stock equivalents comprising shares underlying 12,085,000 options and warrants for the three and six months ended June 30, 2015 have not been included in the loss per share calculations as the effects are anti-dilutive.

<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 27pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Recent Accounting Pronouncements<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 27pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 27pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">In March 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-09, “Compensation – Stock Compensation: Improvements to Employee Share-Based Payment Accounting,” which relates to the accounting for employee share-based payments. This standard addresses several aspects of the accounting for share-based payment award transactions, including: (a) income tax consequences; (b) classification flows of awards as either equity or liabilities; and (c) classification on the statement of cash flows. This standard will be effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. The Company is in the process of evaluating the impact of the adoption of ASU 2016-09 on its consolidated financial statements.<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 27pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 27pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">In February 2016, a pronouncement was issued that creates new accounting and reporting guidelines for leasing arrangements. The new guidance requires organizations that lease assets to recognize assets and liabilities on the balance sheet related to the rights and obligations created by those leases, regardless of whether they are classified as finance or operating leases. Consistent with current guidance, the recognition, measurement, and presentation of expenses and cash flows arising from a lease primarily will depend on its classification as a finance or operating lease. The guidance also requires new disclosures to help financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. The new standard is effective for annual reporting periods beginning after December 15, 2018, including interim periods within that reporting period, with early application permitted. The new standard is to be applied using a modified retrospective approach. The Company is in the process of evaluating the impact of the new pronouncement on its consolidated financial statements.<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 27pt; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 27.35pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">In May 2014, the Financial Accounting Standards Board ("FASB") issued accounting guidance, "Revenue from Contracts with Customers." The core principle of the new standard is for companies to recognize revenue to depict the transfer of goods or services to customers in amounts that reflect the consideration (that is, payment) to which the company expects to be entitled in exchange for those goods or services. The new standard also will result in enhanced disclosures about revenue, provide guidance for transactions that were not previously addressed comprehensively (for example, service revenue and contract modifications) and clarify guidance for multiple-element arrangements. The standard will be effective for fiscal years and interim periods within those years beginning after December 15, 2017. Accordingly, the Company will adopt this standard in the first quarter of fiscal year 2018. The Company is currently evaluating the impact this guidance will have on the consolidated financial statements.<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 27pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 27pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">In July 2015, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2015-11, “Simplifying the Measurement of Inventory.” ASU 2015-11 applies to inventory that is measured using first-in, first-out (FIFO) or average cost.  An entity should measure inventory within the scope of ASU 2015-11 at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation.  ASU 2015-11 is effective for fiscal years beginning after December 15, 2016. The Company is in the process of evaluating the impact of this ASU on its consolidated financial statements.<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 27.35pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 27pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">In August 2014, the FASB issued ASU 2014-15, "Presentation of Financial Statements-Going Concern". This ASU is intended to define management's responsibility to evaluate whether there is substantial doubt about an organization's ability to continue as a going concern and to provide related footnote disclosures. It is effective for annual periods beginning after December 15, 2016, with early adoption permitted. The Company does not expect it to have a material effect on the Company's consolidated financial condition, results of operations, and cash flows.<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 27pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">All other accounting standards that have been issued or proposed by the FASB that do not require adoption until a future date are not expected to have a material impact on the consolidated financial statements upon adoption.

<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 27pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Noncontrolling Interests<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 27pt; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 27pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Company accounts for its less than 100% interest in Immudyne PR in accordance with ASC Topic 810, Consolidation, and accordingly the Company presents noncontrolling interests as a component of equity on its consolidated balance sheet and reports the noncontrolling interest’s share of the Immudyne PR net loss attributable to noncontrolling interests in the consolidated statement of operations.

<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 27.35pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Concentration of Credit Risk<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 27pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 27pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Company grants credit in the normal course of business to its customers. The Company periodically performs credit analysis and monitors the financial condition of its customers to reduce credit risk.<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 27pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 27.35pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Company monitors its positions with, and the credit quality of, the financial institutions with which it invests. The Company, at times, maintains balances in various operating accounts in excess of federally insured limits.<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 27pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 27pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 27pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">One customer in the nutraceutical and cosmetic additives division accounted for 17% and 83% of consolidated sales for each of the three month periods ended June 30, 2016 and 2015, respectively. This customer accounted for 16% and 83% of consolidated sales for the six month periods ended June 30, 2016 and 2015, respectively. This customer accounted for 30% and 43% of accounts receivable at June 30, 2016 and December 31, 2015, respectively.<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 27pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 27pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">A second customer in the nutraceutical and cosmetic additives division accounted for 4% and 12% of consolidated sales for each of the three month periods ended June 30, 2016 and 2015, respectively. This customer accounted for 2% and 12% of consolidated sales for the six month periods ended June 30, 2016 and 2015, respectively. This customer accounted for 0% and 24% of accounts receivable at June 30, 2016 and December 31, 2015, respectively.

<table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: white;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">June 30, 2016</td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">December 31,  2015</td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"> </td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: white;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;" colspan="2"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;" colspan="2"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal; background-color: #cceeff;"><td style="font: 10pt/normal 'times new roman', times, serif; width: 27pt; font-stretch: normal; background-color: white;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">Raw materials</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;">$</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 125px; text-align: right; font-stretch: normal;">56,957</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;">$</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 125px; text-align: right; font-stretch: normal;">25,761</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;"> </td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal; background-color: white;"><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: white;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;">Finished products</td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">122,298</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">35,290</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;"> </td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal; background-color: #cceeff;"><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: white;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">$</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">179,255</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">$</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">61,051</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;"> </td></tr></table>

<table style="font: 10pt/normal times new roman, times, serif; width: 100%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="background-color: white;"> </td> <td style="font-weight: bold; padding-bottom: 1.5pt;">Total assets:</td> <td style="padding-bottom: 1.5pt;"> </td> <td colspan="2"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td colspan="2"> </td> <td style="padding-bottom: 1.5pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="background-color: white;"> </td> <td style="font-weight: bold; padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td colspan="2"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td colspan="2"> </td> <td style="padding-bottom: 1.5pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="background-color: white;"> </td> <td> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center;" colspan="2">June 30, 2016</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center;" colspan="2">December 31, 2015</td> <td style="padding-bottom: 1.5pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="width: 36px; background-color: white;"> </td> <td style="text-align: left;">Nutraceutical and Cosmetic Additives</td> <td style="width: 1%;"> </td> <td style="width: 1%; text-align: left;">$</td> <td style="width: 8%; text-align: right;">417,818</td> <td style="width: 1%; text-align: left;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%; text-align: left;">$</td> <td style="width: 8%; text-align: right;">412,324</td> <td style="width: 1%; text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="background-color: white;"> </td> <td style="text-align: left;">Finished Cosmetic Products</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">562,717</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">101,828</td> <td style="text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="background-color: white;"> </td> <td style="padding-bottom: 1.5pt;">Eliminations</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: left;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right;">(114,754</td> <td style="padding-bottom: 1.5pt; text-align: left;">)</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: left;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right;">(65,681</td> <td style="padding-bottom: 1.5pt; text-align: left;">)</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="background-color: white;"> </td> <td style="font-weight: bold; padding-bottom: 4pt;">Total</td> <td style="font-weight: bold; padding-bottom: 4pt;"> </td> <td style="border-bottom: black 4pt double; font-weight: bold; text-align: left;">$</td> <td style="border-bottom: black 4pt double; font-weight: bold; text-align: right;">865,781</td> <td style="font-weight: bold; padding-bottom: 4pt; text-align: left;"> </td> <td style="font-weight: bold; padding-bottom: 4pt;"> </td> <td style="border-bottom: black 4pt double; font-weight: bold; text-align: left;">$</td> <td style="border-bottom: black 4pt double; font-weight: bold; text-align: right;">448,471</td> <td style="font-weight: bold; padding-bottom: 4pt; text-align: left;"> </td> </tr> </table>   <table style="font: 10pt/normal times new roman, times, serif; width: 100%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="background-color: white;"> </td> <td style="font-weight: bold; padding-bottom: 1.5pt;">Total sales:</td> <td style="padding-bottom: 1.5pt;"> </td> <td colspan="2"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td colspan="2"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td colspan="2"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td colspan="2"> </td> <td style="padding-bottom: 1.5pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="background-color: white;"> </td> <td style="font-weight: bold; padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td colspan="2"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td colspan="2"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td colspan="2"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td colspan="2"> </td> <td style="padding-bottom: 1.5pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="background-color: white;"> </td> <td> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center;" colspan="6">Three months ended</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center;" colspan="6">Six months ended</td> <td style="padding-bottom: 1.5pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="background-color: white;"> </td> <td> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center;" colspan="2">June 30, 2016</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center;" colspan="2">June 30, 2015</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center;" colspan="2">June 30, 2016</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center;" colspan="2">June 30, 2015</td> <td style="padding-bottom: 1.5pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="width: 36px; background-color: white;"> </td> <td style="text-align: left;">Nutraceutical and Cosmetic Additives</td> <td style="width: 1%;"> </td> <td style="width: 1%; text-align: left;">$</td> <td style="width: 8%; text-align: right;">266,060</td> <td style="width: 1%; text-align: left;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%; text-align: left;">$</td> <td style="width: 8%; text-align: right;">277,353</td> <td style="width: 1%; text-align: left;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%; text-align: left;">$</td> <td style="width: 8%; text-align: right;">551,220</td> <td style="width: 1%; text-align: left;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%; text-align: left;">$</td> <td style="width: 8%; text-align: right;">565,630</td> <td style="width: 1%; text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="background-color: white;"> </td> <td style="text-align: left;">Finished Cosmetic Products</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">964,937</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">-</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">2,340,055</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">-</td> <td style="text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="background-color: white;"> </td> <td style="padding-bottom: 1.5pt;">Eliminations</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: left;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right;">(3,750</td> <td style="padding-bottom: 1.5pt; text-align: left;">)</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: left;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right;">-</td> <td style="padding-bottom: 1.5pt; text-align: left;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: left;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right;">(23,000</td> <td style="padding-bottom: 1.5pt; text-align: left;">)</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: left;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right;">-</td> <td style="padding-bottom: 1.5pt; text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="background-color: white;"> </td> <td style="font-weight: bold; padding-bottom: 4pt;">Total</td> <td style="font-weight: bold; padding-bottom: 4pt;"> </td> <td style="border-bottom: black 4pt double; font-weight: bold; text-align: left;">$</td> <td style="border-bottom: black 4pt double; font-weight: bold; text-align: right;">1,227,247</td> <td style="font-weight: bold; padding-bottom: 4pt; text-align: left;"> </td> <td style="font-weight: bold; padding-bottom: 4pt;"> </td> <td style="border-bottom: black 4pt double; font-weight: bold; text-align: left;">$</td> <td style="border-bottom: black 4pt double; font-weight: bold; text-align: right;">277,353</td> <td style="font-weight: bold; padding-bottom: 4pt; text-align: left;"> </td> <td style="font-weight: bold; padding-bottom: 4pt;"> </td> <td style="border-bottom: black 4pt double; font-weight: bold; text-align: left;">$</td> <td style="border-bottom: black 4pt double; font-weight: bold; text-align: right;">2,868,275</td> <td style="font-weight: bold; padding-bottom: 4pt; text-align: left;"> </td> <td style="font-weight: bold; padding-bottom: 4pt;"> </td> <td style="border-bottom: black 4pt double; font-weight: bold; text-align: left;">$</td> <td style="border-bottom: black 4pt double; font-weight: bold; text-align: right;">565,630</td> <td style="font-weight: bold; padding-bottom: 4pt; text-align: left;"> </td> </tr> </table>   <table style="font: 10pt/normal times new roman, times, serif; width: 100%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="background-color: white;"> </td> <td style="font-weight: bold; padding-bottom: 1.5pt;">Net (loss) income:</td> <td style="padding-bottom: 1.5pt;"> </td> <td colspan="2"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td colspan="2"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td colspan="2"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td colspan="2"> </td> <td style="padding-bottom: 1.5pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="background-color: white;"> </td> <td style="font-weight: bold; padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td colspan="2"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td colspan="2"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td colspan="2"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td colspan="2"> </td> <td style="padding-bottom: 1.5pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="background-color: white;"> </td> <td> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center;" colspan="6">Three months ended</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center;" colspan="6">Six months ended</td> <td style="padding-bottom: 1.5pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="background-color: white;"> </td> <td> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center;" colspan="2">June 30, 2016</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center;" colspan="2">June 30, 2015</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center;" colspan="2">June 30, 2016</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center;" colspan="2">June 30, 2015</td> <td style="padding-bottom: 1.5pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="width: 36px; background-color: white;"> </td> <td style="text-align: left;">Nutraceutical and Cosmetic Additives</td> <td style="width: 1%;"> </td> <td style="width: 1%; text-align: left;">$</td> <td style="width: 8%; text-align: right;">(356,049</td> <td style="width: 1%; text-align: left;">)</td> <td style="width: 1%;"> </td> <td style="width: 1%; text-align: left;">$</td> <td style="width: 8%; text-align: right;">(21,028</td> <td style="width: 1%; text-align: left;">)</td> <td style="width: 1%;"> </td> <td style="width: 1%; text-align: left;">$</td> <td style="width: 8%; text-align: right;">(395,043</td> <td style="width: 1%; text-align: left;">)</td> <td style="width: 1%;"> </td> <td style="width: 1%; text-align: left;">$</td> <td style="width: 8%; text-align: right;">(19,362</td> <td style="width: 1%; text-align: left;">)</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="background-color: white;"> </td> <td style="text-align: left;">Finished Cosmetic Products</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">199,668</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">-</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">130,503</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">-</td> <td style="text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="background-color: white;"> </td> <td style="padding-bottom: 1.5pt;">Eliminations</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: left;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right;">-</td> <td style="padding-bottom: 1.5pt; text-align: left;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: left;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right;">-</td> <td style="padding-bottom: 1.5pt; text-align: left;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: left;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right;">-</td> <td style="padding-bottom: 1.5pt; text-align: left;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: left;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right;">-</td> <td style="padding-bottom: 1.5pt; text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="background-color: white;"> </td> <td style="font-weight: bold; padding-bottom: 4pt;">Total</td> <td style="font-weight: bold; padding-bottom: 4pt;"> </td> <td style="border-bottom: black 4pt double; font-weight: bold; text-align: left;">$</td> <td style="border-bottom: black 4pt double; font-weight: bold; text-align: right;">(156,381</td> <td style="font-weight: bold; padding-bottom: 4pt; text-align: left;">)</td> <td style="font-weight: bold; padding-bottom: 4pt;"> </td> <td style="border-bottom: black 4pt double; font-weight: bold; text-align: left;">$</td> <td style="border-bottom: black 4pt double; font-weight: bold; text-align: right;">(21,028</td> <td style="font-weight: bold; padding-bottom: 4pt; text-align: left;">)</td> <td style="font-weight: bold; padding-bottom: 4pt;"> </td> <td style="border-bottom: black 4pt double; font-weight: bold; text-align: left;">$</td> <td style="border-bottom: black 4pt double; font-weight: bold; text-align: right;">(264,540</td> <td style="font-weight: bold; padding-bottom: 4pt; text-align: left;">)</td> <td style="font-weight: bold; padding-bottom: 4pt;"> </td> <td style="border-bottom: black 4pt double; font-weight: bold; text-align: left;">$</td> <td style="border-bottom: black 4pt double; font-weight: bold; text-align: right;">(19,362</td> <td style="font-weight: bold; padding-bottom: 4pt; text-align: left;">)</td> </tr> </table>

<table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: white;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0pt; text-indent: 0pt; font-stretch: normal; background-color: white;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0pt; text-indent: 0pt; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0pt; text-align: center; text-indent: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">Number of Options</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0pt; text-indent: 0pt; font-stretch: normal;"> </td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal; background-color: #cceeff;"><td style="font: 10pt/normal 'times new roman', times, serif; width: 27pt; font-stretch: normal; background-color: white;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0pt; text-indent: 0pt; font-stretch: normal;">Balance at December 31, 2015</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0pt; width: 15px; text-indent: 0pt; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0pt; width: 15px; text-align: left; text-indent: 0pt; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0pt; width: 125px; text-align: right; text-indent: 0pt; font-stretch: normal;">11,025,273</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0pt; width: 15px; text-align: left; text-indent: 0pt; font-stretch: normal;"> </td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal; background-color: white;"><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: white;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0pt; text-indent: 0pt; font-stretch: normal;">Cancelled</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0pt; text-indent: 0pt; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0pt; text-align: left; text-indent: 0pt; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0pt; text-align: right; text-indent: 0pt; font-stretch: normal;">(250,000</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0pt; text-align: left; text-indent: 0pt; font-stretch: normal;">)</td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal; background-color: #cceeff;"><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: white;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0pt; text-indent: 0pt; font-stretch: normal;">Issued</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0pt; text-indent: 0pt; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0pt; text-align: left; text-indent: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0pt; text-align: right; text-indent: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">175,000</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0pt; text-align: left; text-indent: 0pt; font-stretch: normal;"> </td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal; background-color: white;"><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: white;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0pt; text-indent: 0pt; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0pt; text-indent: 0pt; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0pt; text-align: left; text-indent: 0pt; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0pt; text-align: right; text-indent: 0pt; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0pt; text-align: left; text-indent: 0pt; font-stretch: normal;"> </td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal; background-color: #cceeff;"><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: white;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0pt; text-indent: 0pt; font-stretch: normal;">Balance at June 30, 2016</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0pt; text-indent: 0pt; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0pt; text-align: left; text-indent: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0pt; text-align: right; text-indent: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">10,950,273</td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0pt; text-align: left; text-indent: 0pt; font-stretch: normal;"></td></tr></table>

<table style="font: 10pt/normal times new roman, times, serif; width: 100%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="background-color: white;"> </td> <td style="border-bottom: black 1.5pt solid;">Exercise Price</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center;" colspan="2">Number of Options</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center;" colspan="2">Weighted Average Remaining Contractual Life</td> <td style="padding-bottom: 1.5pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="background-color: white;"> </td> <td> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: center;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="width: 36px; background-color: white;"> </td> <td style="text-align: left;">$0.10</td> <td style="width: 1%;"> </td> <td style="width: 1%; text-align: left;"> </td> <td style="width: 8%; text-align: right;">1,680,273</td> <td style="width: 1%; text-align: left;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%; text-align: center;"> </td> <td style="width: 8%; text-align: center;">2 years</td> <td style="width: 1%; text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="background-color: white;"> </td> <td style="text-align: left;">$0.20 - $0.25</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">8,120,000</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: center;"> </td> <td style="text-align: center;">6 years</td> <td style="text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="background-color: white;"> </td> <td style="padding-bottom: 1.5pt; text-align: left;">$0.40</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: left;"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right;">1,150,000</td> <td style="padding-bottom: 1.5pt; text-align: left;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt; text-align: left;"> </td> <td style="padding-bottom: 1.5pt; text-align: center;">5 years</td> <td style="padding-bottom: 1.5pt; text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="background-color: white;"> </td> <td style="padding-bottom: 4pt; text-align: left; padding-left: 10pt;">Total</td> <td style="padding-bottom: 4pt;"> </td> <td style="border-bottom: black 4pt double; text-align: left;"> </td> <td style="border-bottom: black 4pt double; text-align: right;">10,950,273</td> <td style="padding-bottom: 4pt; text-align: left;"> </td> <td style="padding-bottom: 4pt;"> </td> <td style="padding-bottom: 4pt; text-align: left;"> </td> <td style="padding-bottom: 4pt; text-align: right;"> </td> <td style="padding-bottom: 4pt; text-align: left;"> </td> </tr> </table>

0.3333

0.7816667

0.51

25761

56957

35290

122298

448471

412324

101828

-65681

865781

417818

562717

-114754

0.83 0.12 0.17 0.04 0.21833

20000

620000

1050000

12085000

12700273

0.83

0.12

0.83

0.12

0.43

0.24

0.17

0.04

0.16

0.02

0.30

0.00

18000

87000

100000

0.11

8036

122

18342

248

2750

5500

313

2016-11-01

930000

2730000

2035-12-31

0.34

11025273

10950273

1680273

8120000

1150000

250000

175000

4530000

50000

150000

0.0188

2.844

P3Y

0.24

0.10

0.40

0.20

0.25

P2Y

P6Y

P5Y

747294

5000000

10000000

747294

40829

P10Y

2021-12-31

2025-12-31

0.20

0.40

0.80

0.40

0.80

0.20

10000000

116600

57834

1750000

1750000 1750000

0.16

Warrants expire during November 2016 and December 2017. 135567 2 227175 0.08

1157

20157

0.60

56579

84868

499225

0.17

2016-05-31

9000

14468

34929

27284

43900

145000

0.40

0.80

4530000 0.15

The Company has entered into two agreements on April 1, 2016 with two consultants of Immudyne PR for business development, marketing and sales related services (the “Consultant Agreements”). Upon signing, each consultant was issued 1,000,000 restricted shares of Immudyne, Inc. common stock. In addition, each consultant shall receive an additional 150,000 restricted shares of Immudyne, Inc. common stock for each $500,000 distributed by Immudyne PR to the Company. For each consultants the amount of shares to be issued by the Company to the consultants shall be capped at 1,500,000 restricted shares when Immudyne PR has transferred $5,000,000 to the Company, for a combined capped total of 3,000,000 restricted shares. In addition, the Consulting Agreements provided that each consultant shall receive a bonus of an additional 750,000 restricted shares of Immudyne Inc. common stock, plus an option to buy 1,000,000 shares of Immudyne, Inc. common stock at $0.20/share (including a cashless exercise feature) when Immudyne PR has transferred to the Company at each of the following three (3) thresholds: $1,250,000, $2,000,000 and $3,000,000 for a total of 2,250,000 of restricted shares of Immudyne, Inc. common stock and options to purchase up to 3,000,000 shares of Immudyne, Inc. common stock at $0.20/share. As of June 30, 2016, no bonus shares have been issued and no options have been granted under this agreement.

1000000

2300000

750000 1000000 3000 9000 6000 14000

P10Y

91612

-91612

0.00

2000

4000

230000

309695

230000

348562

EX-101.SCH 5 immd-20160630.xsd XBRL SCHEMA FILE 001 - Document - Document and Entity Information link:presentationLink link:definitionLink link:calculationLink 002 - Statement - Consolidated Balance Sheets link:presentationLink link:definitionLink link:calculationLink 003 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 004 - Statement - Consolidated Statements of Operations (Unaudited) link:presentationLink link:definitionLink link:calculationLink 005 - Statement - Consolidated Statement of Stockholders' Equity (Unaudited) link:presentationLink link:definitionLink link:calculationLink 006 - Statement - Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:definitionLink link:calculationLink 007 - Disclosure - Organization and Going Concern link:presentationLink link:definitionLink link:calculationLink 008 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:definitionLink link:calculationLink 009 - Disclosure - Notes Payable link:presentationLink link:definitionLink link:calculationLink 010 - Disclosure - Income Taxes link:presentationLink link:definitionLink link:calculationLink 011 - Disclosure - Stockholders' Equity link:presentationLink link:definitionLink link:calculationLink 012 - Disclosure - Royalties link:presentationLink link:definitionLink link:calculationLink 013 - Disclosure - Commitments and Contingencies link:presentationLink link:definitionLink link:calculationLink 014 - Disclosure - Related Party Transactions link:presentationLink link:definitionLink link:calculationLink 015 - Disclosure - Subsequent Events link:presentationLink link:definitionLink link:calculationLink 016 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:definitionLink link:calculationLink 017 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:definitionLink link:calculationLink 018 - Disclosure - Income Taxes (Tables) link:presentationLink link:definitionLink link:calculationLink 019 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:definitionLink link:calculationLink 020 - Disclosure - Organization and Going Concern (Details) link:presentationLink link:definitionLink link:calculationLink 021 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:definitionLink link:calculationLink 022 - Disclosure - Summary of Significant Accounting Policies (Details 1) link:presentationLink link:definitionLink link:calculationLink 023 - Disclosure - Summary of Significant Accounting Policies (Details Textual) link:presentationLink link:definitionLink link:calculationLink 024 - Disclosure - Notes Payable (Details) link:presentationLink link:definitionLink link:calculationLink 025 - Disclosure - Income Taxes (Details) link:presentationLink link:definitionLink link:calculationLink 026 - Disclosure - Income Taxes (Details Textual) link:presentationLink link:definitionLink link:calculationLink 027 - Disclosure - Stockholders' Equity (Details) link:presentationLink link:definitionLink link:calculationLink 028 - Disclosure - Stockholders' Equity (Details 1) link:presentationLink link:definitionLink link:calculationLink 029 - Disclosure - Stockholders' Equity (Details 2) link:presentationLink link:definitionLink link:calculationLink 030 - Disclosure - Stockholders' Equity (Details Textual) link:presentationLink link:definitionLink link:calculationLink 031 - Disclosure - Royalties (Details) link:presentationLink link:definitionLink link:calculationLink 032 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:definitionLink link:calculationLink 033 - Disclosure - Related Party Transactions (Details) link:presentationLink link:definitionLink link:calculationLink 034 - Disclosure - Subsequent Events (Details) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 6 immd-20160630_cal.xml XBRL CALCULATION FILE EX-101.DEF 7 immd-20160630_def.xml XBRL DEFINITION FILE EX-101.LAB 8 immd-20160630_lab.xml XBRL LABEL FILE Document and Entity Information [Abstract] Entity Registrant Name Entity Central Index Key Amendment Flag Current Fiscal Year End Date Document Type Document Period End Date Document Fiscal Year Focus Document Fiscal Period Focus Entity Filer Category Entity Common Stock, Shares Outstanding Statement of Financial Position [Abstract] Assets [Abstract] ASSETS Assets, Current [Abstract] Current Assets Cash and Cash Equivalents, at Carrying Value Cash Cash at beginning of the period Cash at end of the period Accounts Receivable, Net, Current, Total Trade accounts receivable, net Inventory, Net, Total Inventory, net Inventory, net Inventory, net Assets, Current, Total Total Current Assets Liabilities and Equity [Abstract] LIABILITIES AND STOCKHOLDERS' (DEFICIT) EQUITY LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) Liabilities, Current [Abstract] Current Liabilities Accounts Payable and Accrued Liabilities, Current, Total Accounts payable and accrued expenses Notes Payable, Current Notes payable Beginning Balance Ending Balance Liabilities, Current, Total Total Current Liabilities Stockholders' Equity Attributable to Parent [Abstract] Immudyne, Inc. Stockholders' equity Stockholders' equity Common Stock, Value, Issued Common stock, $0.01 par value; 50,000,000 shares authorized, 34,310,375 and 32,010,375 shares issued and outstanding as of June 30, 2016 and December 31, 2015, respectively Common stock, $0.01 par value; 50,000,000 shares authorized, 30,609,973 shares issued and outstanding at June 30, 2015 Additional Paid in Capital, Total Additional paid-in capital Retained Earnings (Accumulated Deficit) Retained Earnings (Accumulated Deficit) Accumulated (deficit) Accumulated deficit Accumulated (deficit) Stockholders' Equity Attributable to Parent Total Immudyne, Inc. Stockholders' Equity Balance Balance Stockholders' Equity Attributable to Noncontrolling Interest Non-controlling interest Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Total Stockholders' Equity Balance Balance Liabilities and Equity Total Liabilities and Stockholders' Equity Common Stock, Par or Stated Value Per Share Common stock, par value (in dollars per share) Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares, Outstanding Common stock, shares outstanding Income Statement [Abstract] Revenues, Total Total sales Net sales Revenue Cost of Revenue, Total Cost of sales Gross Profit, Total Gross Profit Compensation and Related Expenses Compensation and related expenses Represents the expense recognized during the period arising from equity-based compensation arrangements and related expenses (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees. Compensation and related expenses Professional Fees Professional fees Consulting expense Professional fees General and Administrative Expense, Total General and administrative expenses General and administrative expenses Operating Expenses Total operating expenses Operating Income (Loss), Total Operating (Loss) Operating income (Loss) Interest Expense Interest expense Interest (expense) Income (Loss) from Continuing Operations before Income Taxes, Extraordinary Items, Noncontrolling Interest, Total Net (Loss) Before Taxes Deferred Income Tax Expense (Benefit) Deferred tax benefit Deferred income tax benefit Deferred income tax benefit Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net (loss) Net (Loss) Net (Loss) Net Income (Loss) Attributable to Noncontrolling Interest Net Income (Loss) attributable to noncontrolling interests Net (loss) attributable to noncontrolling interests Net Income (Loss) Attributable to Parent Net (loss) Net (Loss) Net (Loss) attributable to Immudyne, Inc. Net (loss) income Earnings Per Share, Basic and Diluted Basic and diluted (loss) per share attributable to Immudyne, Inc. Earnings Per Share [Abstract] Average number of common shares outstanding Earnings Per Share, Basic Basic Earnings Per Share, Diluted Diluted Statement of Stockholders' Equity [Abstract] Statement [Table] Equity Components [Axis] Equity Component [Domain] Common Stock [Member] Common Stock Additional Paid-in Capital [Member] Additional Paid-in Capital Accumulated (Deficit) [Member] Accumulated (Deficit) Summation [Member] Sub Total Sub total Member. Noncontrolling Interest [Member] Noncontrolling interest Statement [Line Items] Shares, Outstanding Balance, (in shares) Balance (in shares) Adjustments Of Addition Paid In Capital Amortization Of Stock Options Amortization of stock options Amount of decrease in additional paid in capital (APIC) resulting from amortization of stock options. Stock Issued During Period, Value, Issued for Services Common stock issued for services as per agreement Issuance of common stock for services Stock Issued During Period, Shares, Issued for Services Common stock issued for services as per agreement, shares Issuance of common stock for services, shares Noncontrolling Interest, Period Increase (Decrease) Reduction in noncontrolling interest Adjustments to Additional Paid in Capital, Share-based Compensation, Stock Options, Requisite Service Period Recognition Issuance of stock options Noncontrolling Interest, Increase from Subsidiary Equity Issuance Investment in subsidiary by noncontrolling interest Statement Of Cash Flows [Abstract] Net Cash Provided By (Used In) Operating Activities [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES Adjustments To Reconcile Net Income (Loss) To Cash Provided By (Used In) Operating Activities [Abstract] Adjustments to reconcile net (loss) to net cash (used) provided by operating activities Adjustments to reconcile net (loss) to net cash (used) by operating activities Depreciation Depreciation Depreciation Depreciation expense Share-based Compensation Stock based compensation Stock compensation expense Issuance of Stock and Warrants for Services or Claims Issuance of common stock for services Increase (Decrease) In Operating Capital [Abstract] Changes in Assets And Liabilities Increase (Decrease) In Accounts Receivable Trade accounts receivable Increase (Decrease) in Inventories, Total Inventory Increase (Decrease) In Other Accounts Payable and Accrued Liabilities Accounts payable and accrued expenses Net Cash Provided by (Used in) Operating Activities, Total Negative cash flows from operations Net cash (used) by operating activities Net Cash Provided By (Used In) Financing Activities [Abstract] CASH FLOWS FROM FINANCING ACTIVITIES Proceeds from (Payments to) Noncontrolling Interests Investment in subsidiary by noncontrolling interest Increase in notes payable Increase in notes payable Repayments of Notes Payable Repayment of note payable Repayment Repayment of notes payable Proceeds from Issuance of Common Stock Purchase of Company stock Net Cash Provided by (Used in) Financing Activities Net cash provided by financing activities Cash and Cash Equivalents, Period Increase (Decrease), Total Net increase in cash Supplemental Cash Flow Information [Abstract] Supplemental Disclosure of Cash Flow Information Supplemental Cash Flow Information [Abstract] Interest Paid Cash paid during the period for interest Organization and Going Concern [Abstract] Organization, Consolidation and Presentation Of Financial Statements Disclosure [Text Block] Organization and Going Concern Organization and Going Concern Summary of Significant Accounting Policies [Abstract] Significant Accounting Policies [Text Block] Summary of Significant Accounting Policies Notes Payable [Abstract] Debt Disclosure [Text Block] Notes Payable Income Taxes [Abstract] Income Taxes [Abstract] Income Tax Disclosure [Text Block] Income Taxes Stockholders' Equity [Abstract] Stockholders Equity Note Disclosure [Text Block] Stockholders' Equity Royalties [Abstract] Royalties Disclosure [Text Block] Royalties The entire disclosure for royalty agreement during the reporting period. Commitments and Contingencies [Abstract] Commitments and Contingencies [Abstract] Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Related Party Transactions [Abstract] Related Party Transactions Disclosure [Text Block] Related Party Transactions Subsequent Events [Abstract] Subsequent Events [Text Block] Subsequent Events Unaudited Interim Financial Statements [Policy Text Block] Unaudited Financial Statements Disclosure of accounting policy pertaining to unaudited interim financial statements. Basis Of Presentation and Use Of Estimates Policy [Policy Text Block] Basis of Presentation and Use of Estimates Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements and use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles. Inventory, Policy [Policy Text Block] Inventory Revenue Recognition, Policy [Policy Text Block] Revenue Recognition Trade and Other Accounts Receivable, Policy [Policy Text Block] Accounts receivable Segment Reporting, Policy [Policy Text Block] Segments Income Tax, Policy [Policy Text Block] Income Taxes Compensation Related Costs, Policy [Policy Text Block] Stock-Based Compensation Earnings Per Share, Policy [Policy Text Block] Earnings (Loss) Per Share New Accounting Pronouncements, Policy [Policy Text Block] Recent Accounting Pronouncements Fair Value Of Financial Instruments, Policy [Policy Text Block] Fair Value of Financial Instruments Minority Interest [Policy Text Block] Noncontrolling Interests Disclosure of noncontrolling interests policy for credit risk. Concentration Risk, Credit Risk, Policy [Policy Text Block] Concentration of Credit Risk Concentration Risk, Credit Risk, Policy [Policy Text Block] Schedule Of Inventory, Current [Table Text Block] Summary of inventory Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block] Summary of reportable segments Schedule Of Deferred Tax Assets and Liabilities [Table Text Block] Schedule of deferred tax asset Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Award Type [Axis] Equity Award [Domain] Employee Stock Option [Member] Stock Options [Member] Option [Member] Service-Based Stock Options [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] Summary of outstanding service-based options Schedule of Assumptions Used [Table Text Block] Summary of significant assumptions used to determine fair values of options issued using Black-Scholes option-pricing model Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block] Summary of outstanding service-based options exercise price Schedule of Related Party Transactions, by Related Party [Table] Related Party [Axis] Related Party [Domain] Immudyne Pr Llc [Member] Immudyne PR LLC [Member] Immudyne PR LLC. Related Party Transaction [Line Items] Organization And Going Concern Textual [Abstract] Organization and Going Concern (Textual) organization and going concern textual. Equity Method Investment, Ownership Percentage Percentage of ownership of equity interest Noncontrolling Interest, Ownership Percentage by Parent Percentage of voting controlling interest Inventory, Net [Abstract] Summary of inventory Inventory, Raw Materials, Gross Raw materials Inventory, Finished Goods, Gross Finished products Schedule of Revenue by Major Customers, by Reporting Segments [Table] Consolidation Items [Axis] Consolidation Items [Domain] Nutraceutical And Cosmetic [Member] Nutraceutical and cosmetic [Member] Nutraceutical and cosmetic member. Cosmetic Goods [Member] Finished Cosmetic Products [Member] Cosmetic goods member. Intersegment Eliminations [Member] Elimination [Member] Revenue, Major Customer [Line Items] Summary of reportable segments [Line Items] Assets, Total Total assets Total Assets Option Indexed to Issuer's Equity [Table] Option Indexed to Issuer's Equity, Type [Axis] Option Indexed to Issuer's Equity, Type [Domain] Warrant [Member] Warrant [Member] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Domain] Sales [Member] Accounts Receivable [Member] Concentration Risk Number Of Customers [Axis] Concentration Risk Number Of Customers [Domain] One Customer [Member] Second Customer [Member] Option Indexed to Issuer's Equity [Line Items] Summary Of Significant Accounting Policies Textual [Abstract] Summary of Significant Accounting Policies (Textual) Summary of significant accounting policies textual. Minority Interest Rate Non controlling interest rate Non controlling stated interest rate. Inventory, LIFO Reserve Inventory reserve Sales Discounts, Returns and Allowances, Goods Customer discounts, returns and rebates Antidilutive Securities Excluded From Computation Of Earnings Per Share, Amount Antidilutive securities excluded from computation of earnings per share Concentration Risk, Percentage Concentration risk percentage Accounts Receivable, Net Accounts receivable reserve Schedule of Long-term Debt Instruments [Table] Title of Individual [Axis] Relationship to Entity [Domain] Board of Directors Chairman [Member] Officers, Directors and Other [Member] Debt Instrument [Line Items] Notes Payable Textual [Abstract] Notes Payable (Textual) Notes Payable (Textual) Notes payable textual. Proceeds from Notes Payable Borrowed Borrowed from commercial lender Debt Instrument, Interest Rate, Stated Percentage Interest rate on notes payable Interest rate on notes payable Interest Expense, Debt Interest expense on notes payable Interest expense on notes payable Debt Instrument, Maturity Date Maturity date on notes payable Components of Deferred Tax Assets [Abstract] Schedule of deferred tax assets Deferred Tax Assets, Deferred Income Deferred Tax Asset Deferred Tax Assets, Valuation Allowance Valuation allowance Deferred Tax Assets, Net of Valuation Allowance, Total Total Income Taxes Textual [Abstract] Income Taxes (Textual) Operating Loss Carryforwards Net operating loss carryforwards Operating Loss Carryforwards, Expiration Date Operating loss carryforwards, expiration date Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Percentage of tax rate Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Number of Options Warrants outstanding Number of Options, Beginning balance Number of Options, Ending balance EX-101.PRE 9 immd-20160630_pre.xml XBRL PRESENTATION FILE XML 10 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2016	Aug. 15, 2016
Document and Entity Information [Abstract]
Entity Registrant Name	Immudyne, Inc.
Entity Central Index Key	0000948320
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Type	10-Q
Document Period End Date	Jun. 30, 2016
Document Fiscal Year Focus	2016
Document Fiscal Period Focus	Q2
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		34,310,375

XML 11 R2.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets - USD ($)	Jun. 30, 2016	Dec. 31, 2015
Current Assets
Cash	$ 235,452	$ 232,984
Trade accounts receivable, net	451,074	154,436
Inventory, net	179,255	61,051
Total Current Assets	865,781	448,471
Current Liabilities
Accounts payable and accrued expenses	421,640	167,481
Notes payable	100,000	100,000
Total Current Liabilities	521,640	267,481
Immudyne, Inc. Stockholders' equity
Common stock, $0.01 par value; 50,000,000 shares authorized, 34,310,375 and 32,010,375 shares issued and outstanding as of June 30, 2016 and December 31, 2015, respectively	343,103	320,103
Additional paid-in capital	8,783,487	8,366,313
Accumulated (deficit)	(8,848,363)	(8,586,338)
Total Immudyne, Inc. Stockholders' Equity	278,227	100,078
Non-controlling interest	65,914	80,912
Total Stockholders' Equity	344,141	180,990
Total Liabilities and Stockholders' Equity	$ 865,781	$ 448,471

XML 12 R3.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2016	Dec. 31, 2015
Statement of Financial Position [Abstract]
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized	50,000,000	50,000,000
Common stock, shares issued	34,310,375	32,010,375
Common stock, shares outstanding	34,310,375	32,010,375

XML 13 R4.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Income Statement [Abstract]
Net sales	$ 1,227,247	$ 277,353	$ 2,868,275	$ 565,630
Cost of sales	700,977	89,503	2,038,919	163,719
Gross Profit	526,270	187,850	829,356	401,911
Compensation and related expenses	475,056	114,774	715,511	200,164
Professional fees	125,359	26,314	194,674	61,822
General and administrative expenses	79,487	63,932	177,899	149,261
Total operating expenses	679,902	205,020	1,088,084	411,247
Operating (Loss)	(153,632)	(17,170)	(258,728)	(9,336)
Interest (expense)	(2,750)	(8,158)	(5,813)	(18,626)
Net (Loss) Before Taxes	(156,382)	(25,328)	(264,541)	(27,962)
Deferred income tax benefit		4,300		8,600
Net (Loss)	(156,382)	(21,028)	(264,541)	(19,362)
Net Income (Loss) attributable to noncontrolling interests	43,594		(2,516)
Net (Loss) attributable to Immudyne, Inc.	$ (199,976)	$ (21,028)	$ (262,025)	$ (19,362)
Basic and diluted (loss) per share attributable to Immudyne, Inc.	$ (0.01)	$ 0.00	$ (0.01)	$ 0.00
Average number of common shares outstanding
Basic	32,338,946	30,650,000	32,174,661	30,204,973
Diluted	$ 32,338,946	$ 30,650,000	$ 32,174,661	$ 30,204,973

XML 14 R5.htm IDEA: XBRL DOCUMENT

Consolidated Statement of Stockholders' Equity (Unaudited) - 6 months ended Jun. 30, 2016 - USD ($)	Total	Common Stock	Additional Paid-in Capital	Accumulated (Deficit)	Sub Total	Noncontrolling interest
Balance at Dec. 31, 2015	$ 180,990	$ 320,103	$ 8,366,313	$ (8,586,338)	$ 100,078	$ 80,912
Balance, (in shares) at Dec. 31, 2015		32,010,375
Amortization of stock options	77,733		77,733		77,733
Issuance of common stock for services	230,000	$ 23,000	207,000		230,000
Issuance of common stock for services, shares		2,300,000
Reduction in noncontrolling interest			91,612		91,612	(91,612)
Issuance of stock options	40,829		40,829		40,829
Investment in subsidiary by noncontrolling interest	79,130					79,130
Net (loss)	(264,541)			(262,025)	(262,025)	(2,516)
Balance at Jun. 30, 2016	$ 344,141	$ 343,103	$ 8,783,487	$ (8,848,363)	$ 278,227	$ 65,914
Balance (in shares) at Jun. 30, 2016		34,310,375

XML 15 R6.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
CASH FLOWS FROM OPERATING ACTIVITIES
Net (Loss)	$ (264,541)	$ (19,362)
Adjustments to reconcile net (loss) to net cash (used) by operating activities
Depreciation		28,487
Deferred tax benefit		(8,600)
Stock compensation expense	118,562	4,000
Issuance of common stock for services	230,000
Changes in Assets And Liabilities
Trade accounts receivable	(296,638)	(120,355)
Inventory	(118,204)	19,529
Accounts payable and accrued expenses	254,159	39,868
Net cash (used) by operating activities	(76,662)	(56,433)
CASH FLOWS FROM FINANCING ACTIVITIES
Investment in subsidiary by noncontrolling interest	79,130
Increase in notes payable		130,000
Repayment of notes payable		(58,714)
Purchase of Company stock		(10,800)
Net cash provided by financing activities	79,130	60,486
Net increase in cash	2,468	4,053
Cash at beginning of the period	232,984	75,495
Cash at end of the period	235,452	79,548
Supplemental Disclosure of Cash Flow Information
Cash paid during the period for interest	$ 5,813	$ 18,626

XML 16 R7.htm IDEA: XBRL DOCUMENT

Organization and Going Concern

6 Months Ended

Jun. 30, 2016

Organization and Going Concern [Abstract]

Organization and Going Concern

1.	Organization and Going Concern

XML 17 R8.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies

6 Months Ended

Jun. 30, 2016

Summary of Significant Accounting Policies [Abstract]

Summary of Significant Accounting Policies

2.	Summary of Significant Accounting Policies

Unaudited Financial Statements

Basis of Presentation and Use of Estimates

Inventory

	June 30, 2016		December 31, 2015

Raw materials	$	56,957	$	25,761
Finished products		122,298		35,290
	$	179,255	$	61,051

Revenue Recognition

Accounts receivable

Segments

A summary of the company’s reportable segments is as follows:

Total assets:

	June 30, 2016			December 31, 2015
Nutraceutical and Cosmetic Additives	$	417,818		$	412,324
Finished Cosmetic Products		562,717			101,828
Eliminations		(114,754	)		(65,681	)
Total	$	865,781		$	448,471

Total sales:

	Three months ended					Six months ended
	June 30, 2016			June 30, 2015		June 30, 2016			June 30, 2015
Nutraceutical and Cosmetic Additives	$	266,060		$	277,353	$	551,220		$	565,630
Finished Cosmetic Products		964,937			-		2,340,055			-
Eliminations		(3,750	)		-		(23,000	)		-
Total	$	1,227,247		$	277,353	$	2,868,275		$	565,630

Net (loss) income:

	Three months ended						Six months ended
	June 30, 2016			June 30, 2015			June 30, 2016			June 30, 2015
Nutraceutical and Cosmetic Additives	$	(356,049	)	$	(21,028	)	$	(395,043	)	$	(19,362	)
Finished Cosmetic Products		199,668			-			130,503			-
Eliminations		-			-			-			-
Total	$	(156,381	)	$	(21,028	)	$	(264,540	)	$	(19,362	)

As of and for the six months ended June 30, 2015, there were no assets, sales or net loss relative to the finished cosmetic products segment.

Income Taxes

The Company’s tax returns for all years since December 31, 2012, remain open to taxing authorities.

Stock-Based Compensation

Many of the assumptions require significant judgment and any changes could have a material impact in the determination of stock-based compensation expense.

Earnings (Loss) Per Share

Recent Accounting Pronouncements

Fair Value of Financial Instruments

Noncontrolling Interests

Concentration of Credit Risk

XML 18 R9.htm IDEA: XBRL DOCUMENT

Notes Payable

6 Months Ended

Jun. 30, 2016

Notes Payable [Abstract]

Notes Payable

3.	Notes Payable

XML 19 R10.htm IDEA: XBRL DOCUMENT

Income Taxes

6 Months Ended

Jun. 30, 2016

Income Taxes [Abstract]

Income Taxes

4.	Income Taxes

A summary of the deferred tax asset using an approximate 34% tax rate is as follows:

Deferred Tax Asset	$	930,000
Valuation allowance		(930,000	)
Total	$	-

The net operating loss carryforwards could be subject to limitation in any given year in the event of a change in ownership as defined by IRC Section 382.

The deferred tax benefit included in the statement of operations represents the change in the deferred tax liability at each balance sheet date.

XML 20 R11.htm IDEA: XBRL DOCUMENT

Stockholders' Equity

6 Months Ended

Jun. 30, 2016

Stockholders' Equity [Abstract]

Stockholders' Equity

5.	Stockholders’ Equity

Service-Based Stock Options

A Summary of the outstanding service-based options are as follows:

	Number of Options
Balance at December 31, 2015		11,025,273
Cancelled		(250,000	)
Issued		175,000

Balance at June 30, 2016		10,950,273

The significant assumptions used to determine the fair values of options issued, using a Black-Scholes option-pricing model are as follows:

Significant assumptions :
Risk-free interest rate at grant date		1.88	%
Expected stock price volatility		248.4	%
Expected dividend payout		—
Expected option life-years		3
Weighted average grant date fair value	$	0.24
Forfeiture rate		0	%

The following is a summary of outstanding service-based options at June 30, 2016:

Exercise Price	Number of Options		Weighted Average Remaining Contractual Life

$0.10		1,680,273		2 years
$0.20 - $0.25		8,120,000		6 years
$0.40		1,150,000		5 years
Total		10,950,273

Performance-Based Stock Options

Warrants

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74567-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

+ Details

XML 21 R12.htm IDEA: XBRL DOCUMENT

Royalties

6 Months Ended

Jun. 30, 2016

Royalties [Abstract]

Royalties

6.	Royalties

Included in accounts payable and accrued expenses at June 30, 2016 and December 31, 2015 was $56,579 in regards to this agreement.

XML 22 R13.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

6 Months Ended

Jun. 30, 2016

Commitments and Contingencies [Abstract]

Commitments and Contingencies

7.	Commitments and Contingencies

Leases

Employment and Consulting Agreements

Restricted Stock and Options

Legal Matters

XML 23 R14.htm IDEA: XBRL DOCUMENT

Related Party Transactions

6 Months Ended

Jun. 30, 2016

Related Party Transactions

8.	Related Party Transactions

XML 24 R15.htm IDEA: XBRL DOCUMENT

Subsequent Events

6 Months Ended

Jun. 30, 2016

Subsequent Events [Abstract]

Subsequent Events

9.	Subsequent Events

XML 25 R16.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Policies)

6 Months Ended

Jun. 30, 2016

Summary of Significant Accounting Policies [Abstract]

Unaudited Financial Statements

Unaudited Financial Statements

Basis of Presentation and Use of Estimates

Basis of Presentation and Use of Estimates

Inventory

Inventory

	June 30, 2016		December 31, 2015

Raw materials	$	56,957	$	25,761
Finished products		122,298		35,290
	$	179,255	$	61,051

Revenue Recognition

Revenue Recognition

Accounts receivable

Accounts receivable

Segments

Segments

A summary of the company’s reportable segments is as follows:

Total assets:

	June 30, 2016			December 31, 2015
Nutraceutical and Cosmetic Additives	$	417,818		$	412,324
Finished Cosmetic Products		562,717			101,828
Eliminations		(114,754	)		(65,681	)
Total	$	865,781		$	448,471

Total sales:

	Three months ended					Six months ended
	June 30, 2016			June 30, 2015		June 30, 2016			June 30, 2015
Nutraceutical and Cosmetic Additives	$	266,060		$	277,353	$	551,220		$	565,630
Finished Cosmetic Products		964,937			-		2,340,055			-
Eliminations		(3,750	)		-		(23,000	)		-
Total	$	1,227,247		$	277,353	$	2,868,275		$	565,630

Net (loss) income:

	Three months ended						Six months ended
	June 30, 2016			June 30, 2015			June 30, 2016			June 30, 2015
Nutraceutical and Cosmetic Additives	$	(356,049	)	$	(21,028	)	$	(395,043	)	$	(19,362	)
Finished Cosmetic Products		199,668			-			130,503			-
Eliminations		-			-			-			-
Total	$	(156,381	)	$	(21,028	)	$	(264,540	)	$	(19,362	)

As of and for the six months ended June 30, 2015, there were no assets, sales or net loss relative to the finished cosmetic products segment.

Income Taxes

Income Taxes

ASC 740 also provides a recognition threshold and measurement attribute for the financial statement recognition of a tax position taken or expected to be taken in a tax return. Using this guidance, a company may recognize the tax benefit from an uncertain tax position in its financial statements only if it is more likely-than-not (i.e., a likelihood of more than 50%) that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position.

The Company’s tax returns for all years since December 31, 2012, remain open to taxing authorities.

Stock-Based Compensation

Stock-Based Compensation

Many of the assumptions require significant judgment and any changes could have a material impact in the determination of stock-based compensation expense.

Earnings (Loss) Per Share

Earnings (Loss) Per Share

Recent Accounting Pronouncements

Recent Accounting Pronouncements

Fair Value of Financial Instruments

Fair Value of Financial Instruments

Noncontrolling Interests

Noncontrolling Interests

Concentration of Credit Risk

Concentration of Credit Risk

XML 26 R17.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Tables)

6 Months Ended

Jun. 30, 2016

Summary of Significant Accounting Policies [Abstract]

Summary of inventory

	June 30, 2016		December 31, 2015

Raw materials	$	56,957	$	25,761
Finished products		122,298		35,290
	$	179,255	$	61,051

Summary of reportable segments

Total assets:

	June 30, 2016			December 31, 2015
Nutraceutical and Cosmetic Additives	$	417,818		$	412,324
Finished Cosmetic Products		562,717			101,828
Eliminations		(114,754	)		(65,681	)
Total	$	865,781		$	448,471

Total sales:

	Three months ended					Six months ended
	June 30, 2016			June 30, 2015		June 30, 2016			June 30, 2015
Nutraceutical and Cosmetic Additives	$	266,060		$	277,353	$	551,220		$	565,630
Finished Cosmetic Products		964,937			-		2,340,055			-
Eliminations		(3,750	)		-		(23,000	)		-
Total	$	1,227,247		$	277,353	$	2,868,275		$	565,630

Net (loss) income:

	Three months ended						Six months ended
	June 30, 2016			June 30, 2015			June 30, 2016			June 30, 2015
Nutraceutical and Cosmetic Additives	$	(356,049	)	$	(21,028	)	$	(395,043	)	$	(19,362	)
Finished Cosmetic Products		199,668			-			130,503			-
Eliminations		-			-			-			-
Total	$	(156,381	)	$	(21,028	)	$	(264,540	)	$	(19,362	)

XML 27 R18.htm IDEA: XBRL DOCUMENT

Income Taxes (Tables)

6 Months Ended

Jun. 30, 2016

Income Taxes [Abstract]

Schedule of deferred tax asset

Deferred Tax Asset	$	930,000
Valuation allowance		(930,000	)
Total	$	-

XML 28 R19.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Tables)

6 Months Ended

Jun. 30, 2016

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Summary of significant assumptions used to determine fair values of options issued using Black-Scholes option-pricing model

Significant assumptions :
Risk-free interest rate at grant date		1.88	%
Expected stock price volatility		248.4	%
Expected dividend payout		—
Expected option life-years		3
Weighted average grant date fair value	$	0.24
Forfeiture rate		0	%

Summary of outstanding service-based options exercise price

Exercise Price	Number of Options		Weighted Average Remaining Contractual Life

$0.10		1,680,273		2 years
$0.20 - $0.25		8,120,000		6 years
$0.40		1,150,000		5 years
Total		10,950,273

Service-Based Stock Options [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Summary of outstanding service-based options

	Number of Options
Balance at December 31, 2015		11,025,273
Cancelled		(250,000	)
Issued		175,000

Balance at June 30, 2016		10,950,273

XML 29 R20.htm IDEA: XBRL DOCUMENT

Organization and Going Concern (Details) - USD ($)	Jun. 30, 2016	Apr. 01, 2016	Dec. 31, 2015
Organization and Going Concern (Textual)
Percentage of ownership of equity interest			33.33%
Percentage of voting controlling interest			51.00%
Accumulated deficit	$ (8,848,363)		$ (8,586,338)
Immudyne Pr Llc [Member]
Organization and Going Concern (Textual)
Percentage of ownership of equity interest		78.16667%

XML 30 R21.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Details) - USD ($)	Jun. 30, 2016	Dec. 31, 2015
Summary of inventory
Raw materials	$ 56,957	$ 25,761
Finished products	122,298	35,290
Inventory, net	$ 179,255	$ 61,051

XML 31 R22.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Details 1) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2015
Summary of reportable segments [Line Items]
Total assets	$ 865,781		$ 865,781		$ 448,471
Total sales	1,227,247	$ 277,353	2,868,275	$ 565,630
Net (loss) income	(199,976)	(21,028)	(262,025)	(19,362)
Nutraceutical and cosmetic [Member]
Summary of reportable segments [Line Items]
Total assets	417,818		417,818		412,324
Total sales	266,060	277,353	551,220	565,630
Net (loss) income	(356,049)	(21,028)	(395,043)	(19,362)
Finished Cosmetic Products [Member]
Summary of reportable segments [Line Items]
Total assets	562,717		562,717		101,828
Total sales	964,937		2,340,055
Net (loss) income	199,668		130,503
Elimination [Member]
Summary of reportable segments [Line Items]
Total assets	(114,754)		(114,754)		$ (65,681)
Total sales	(3,750)		(23,000)
Net (loss) income

XML 32 R23.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Details Textual) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2015
Summary of Significant Accounting Policies (Textual)
Non controlling interest rate			21.833%
Inventory reserve	$ 20,000		$ 20,000		$ 20,000
Customer discounts, returns and rebates	620,000		1,050,000
Revenue	1,227,247	$ 277,353	2,868,275	$ 565,630
Accounts receivable reserve	87,000		87,000		$ 18,000
Nutraceutical and cosmetic [Member]
Summary of Significant Accounting Policies (Textual)
Revenue	266,060	277,353	551,220	565,630
Finished Cosmetic Products [Member]
Summary of Significant Accounting Policies (Textual)
Revenue	$ 964,937		$ 2,340,055
Sales [Member] \| One Customer [Member] \| Nutraceutical and cosmetic [Member]
Summary of Significant Accounting Policies (Textual)
Concentration risk percentage	17.00%	83.00%	16.00%	83.00%
Sales [Member] \| Second Customer [Member] \| Nutraceutical and cosmetic [Member]
Summary of Significant Accounting Policies (Textual)
Concentration risk percentage	4.00%	12.00%	2.00%	12.00%
Accounts Receivable [Member] \| One Customer [Member]
Summary of Significant Accounting Policies (Textual)
Concentration risk percentage			30.00%		43.00%
Accounts Receivable [Member] \| One Customer [Member] \| Nutraceutical and cosmetic [Member]
Summary of Significant Accounting Policies (Textual)
Non controlling interest rate	17.00%	83.00%
Accounts Receivable [Member] \| Second Customer [Member]
Summary of Significant Accounting Policies (Textual)
Concentration risk percentage			0.00%		24.00%
Accounts Receivable [Member] \| Second Customer [Member] \| Nutraceutical and cosmetic [Member]
Summary of Significant Accounting Policies (Textual)
Non controlling interest rate	4.00%	12.00%
Option [Member] \| Warrant [Member]
Summary of Significant Accounting Policies (Textual)
Antidilutive securities excluded from computation of earnings per share	12,700,273	12,085,000	12,700,273	12,085,000

XML 33 R24.htm IDEA: XBRL DOCUMENT

Notes Payable (Details) - USD ($)	1 Months Ended	3 Months Ended		6 Months Ended
Notes Payable (Details) - USD ($)	Nov. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Notes Payable (Textual)
Borrowed from commercial lender	$ 100,000
Interest rate on notes payable	11.00%
Interest expense on notes payable		$ 2,750	$ 8,036	$ 5,500	$ 18,342
Maturity date on notes payable	Nov. 01, 2016
Interest expense		2,750	8,158	5,813	18,626
Officers, Directors and Other [Member]
Notes Payable (Textual)
Interest expense on notes payable		$ 0	$ 122	$ 313	$ 248

XML 34 R25.htm IDEA: XBRL DOCUMENT

Income Taxes (Details)	Jun. 30, 2016 USD ($)
Schedule of deferred tax assets
Deferred Tax Asset	$ 930,000
Valuation allowance	(930,000)
Total

XML 35 R26.htm IDEA: XBRL DOCUMENT

Income Taxes (Details Textual) - USD ($)	6 Months Ended	12 Months Ended
Income Taxes (Details Textual) - USD ($)	Jun. 30, 2016	Dec. 31, 2015
Income Taxes (Textual)
Net operating loss carryforwards		$ 2,730,000
Operating loss carryforwards, expiration date		Dec. 31, 2035
Percentage of tax rate	34.00%

XML 36 R27.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Details) - Service-Based Stock Options [Member] - shares	1 Months Ended	6 Months Ended
	May 31, 2016	Jun. 30, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options, Beginning balance		11,025,273
Number of Options, Cancelled		(250,000)
Number of Options, Issued	175,000
Number of Options, Ending balance		10,950,273

XML 37 R28.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Details 1)	6 Months Ended
Stockholders' Equity (Details 1)	Jun. 30, 2016 $ / shares
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Risk-free interest rate at grant date	1.88%
Expected stock price volatility	284.40%
Expected dividend payout
Expected option life-years	3 years
Weighted average grant date fair value	$ 0.24
Forfeiture rate	0.00%

XML 38 R29.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Details 2) - $ / shares	6 Months Ended
Stockholders' Equity (Details 2) - $ / shares	Jun. 30, 2016	Dec. 31, 2015
Employee Stock Option [Member]
Summary of outstanding service-based options
Number of Options	10,950,273	11,025,273
$0.10 [Member]
Summary of outstanding service-based options
Exercise Price	$ 0.10
Number of Options	1,680,273
Weighted Average Remaining Contractual Life	2 years
$0.20 - $0.25 [Member]
Summary of outstanding service-based options
Number of Options	8,120,000
Weighted Average Remaining Contractual Life	6 years
$0.20 - $0.25 [Member] \| Minimum [Member]
Summary of outstanding service-based options
Exercise Price	$ 0.20
$0.20 - $0.25 [Member] \| Maximum [Member]
Summary of outstanding service-based options
Exercise Price	0.25
$0.40 [Member]
Summary of outstanding service-based options
Exercise Price	$ 0.40
Number of Options	1,150,000
Weighted Average Remaining Contractual Life	5 years

XML 39 R30.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Details Textual)		1 Months Ended	3 Months Ended		6 Months Ended
Stockholders' Equity (Details Textual)	Apr. 01, 2016 shares	May 31, 2016 USD ($) $ / shares shares	Jun. 30, 2016 USD ($) $ / shares shares	Jun. 30, 2015 USD ($)	Jun. 30, 2016 USD ($) Consultants $ / shares shares	Jun. 30, 2015 USD ($)	Dec. 31, 2015 shares
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Common stock issued for services as per agreement					$ 230,000
Stock based compensation expense			$ 230,000		230,000
Intrinsic value of options exercisable			747,294		747,294
Intrinsic value of options outstanding			747,294		747,294
Stock based compensation					118,562	$ 4,000
Unearned share based compensation			116,600		$ 116,600
Number of consultant \| Consultants					2
Two consultants [Member]
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Common stock issued for services as per agreement, shares \| shares	2,300,000
Performance Based Stock Options [Member]
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Stock based compensation expense			309,695	$ 2,000	$ 348,562	$ 4,000
Number of stock options issued \| shares					4,530,000
Stock based compensation			38,867		$ 77,733
Unearned share based compensation			57,834		57,834
Fair value of performance-based stock options					$ 135,567
Performance Based Stock Options [Member] \| Minimum [Member]
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Stock options, Expiration date					Dec. 31, 2021
Weighted average exercise price stock option issued \| $ / shares					$ 0.40
Performance Based Stock Options [Member] \| Maximum [Member]
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Stock options, Expiration date					Dec. 31, 2025
Weighted average exercise price stock option issued \| $ / shares					$ 0.80
Annual sales revenue target					$ 10,000,000
Service-Based Stock Options [Member]
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Number of stock options issued \| shares		175,000
Stock option issued, value		$ 40,829
Stock options, Expiration period		10 years
Weighted average exercise price stock option issued \| $ / shares		$ 0.20
Stock based compensation			$ 40,829		$ 40,829
Warrant [Member]
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Warrants outstanding \| shares			1,750,000		1,750,000		1,750,000
Warrant exercisable \| shares			1,750,000		1,750,000		1,750,000
Weighted average exercise price of warrants outstanding \| $ / shares			$ 0.16		$ 0.16
Warrant expiration date, description					Warrants expire during November 2016 and December 2017.

XML 40 R31.htm IDEA: XBRL DOCUMENT

Royalties (Details) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
Royalties (Details) - USD ($)	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2015
Royalties (Textual)
Royalty based upon sales amount			$ 227,175
Percentage of royalty based upon sales			8.00%
Royalty expense	$ 0	$ 1,157	$ 0	$ 20,157
Accounts payable and accrued expenses	$ 56,579		$ 56,579		$ 56,579
President [Member]
Royalties (Textual)
Interest in royalty					60.00%
Royalties payable					$ 84,868
Common stock shares issued					499,225
Stock price per share					$ 0.17

XML 41 R32.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Details) - USD ($)		3 Months Ended		6 Months Ended
Commitments and Contingencies (Details) - USD ($)	Apr. 01, 2016	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Commitments and Contingencies (Textual)
Lease expiration date				May 31, 2016
Monthly lease rental payments				$ 9,000
Operating leases, rent expense		$ 27,284	$ 14,468	43,900	$ 34,929
Salaries, wages and officers compensation				$ 145,000
Stock option exercise price lower range limit				$ 0.40
Stock option exercise price upper range limit				$ 0.80
Stock issued during period performance based options to purchase common stock		4,530,000		4,530,000
Percentage of bonus compensation for pretax income				15.00%
Restricted Stock and Options [Member]
Commitments and Contingencies (Textual)
Consultant agreements Description				The Company has entered into two agreements on April 1, 2016 with two consultants of Immudyne PR for business development, marketing and sales related services (the “Consultant Agreements”). Upon signing, each consultant was issued 1,000,000 restricted shares of Immudyne, Inc. common stock. In addition, each consultant shall receive an additional 150,000 restricted shares of Immudyne, Inc. common stock for each $500,000 distributed by Immudyne PR to the Company. For each consultants the amount of shares to be issued by the Company to the consultants shall be capped at 1,500,000 restricted shares when Immudyne PR has transferred $5,000,000 to the Company, for a combined capped total of 3,000,000 restricted shares. In addition, the Consulting Agreements provided that each consultant shall receive a bonus of an additional 750,000 restricted shares of Immudyne Inc. common stock, plus an option to buy 1,000,000 shares of Immudyne, Inc. common stock at $0.20/share (including a cashless exercise feature) when Immudyne PR has transferred to the Company at each of the following three (3) thresholds: $1,250,000, $2,000,000 and $3,000,000 for a total of 2,250,000 of restricted shares of Immudyne, Inc. common stock and options to purchase up to 3,000,000 shares of Immudyne, Inc. common stock at $0.20/share. As of June 30, 2016, no bonus shares have been issued and no options have been granted under this agreement.
Restricted shares issued	1,000,000			2,300,000
Additional bonus shares				750,000
Option to buy shares				1,000,000

XML 42 R33.htm IDEA: XBRL DOCUMENT

Related Party Transactions (Details) - USD ($)	3 Months Ended	6 Months Ended
Related Party Transactions (Details) - USD ($)	Jun. 30, 2016	Jun. 30, 2016
Related Party Transactions (Textual)
Compensation for legal services provided by director	$ 3,000	$ 9,000
Reimbursement of home office expenditures received by director	$ 6,000	$ 14,000

XML 43 R34.htm IDEA: XBRL DOCUMENT

Subsequent Events (Details) - USD ($)		6 Months Ended
Subsequent Events (Details) - USD ($)	Jul. 01, 2016	Jun. 30, 2016
Subsequent Events (Textual)
Exercisable sales revenue		$ 747,294
Performance Based Stock Options [Member]
Subsequent Events (Textual)
Number of Options, Issued		4,530,000
Performance Based Stock Options [Member] \| Minimum [Member]
Subsequent Events (Textual)
Exercise price, Granted		$ 0.40
Performance Based Stock Options [Member] \| Maximum [Member]
Subsequent Events (Textual)
Exercise price, Granted		$ 0.80
Subsequent Event [Member] \| Performance Based Stock Options [Member]
Subsequent Events (Textual)
Number of Options, Issued	150,000
Expire term	10 years
Subsequent Event [Member] \| Performance Based Stock Options [Member] \| Minimum [Member]
Subsequent Events (Textual)
Exercise price, Granted	$ 0.40
Exercisable sales revenue	$ 5,000,000
Subsequent Event [Member] \| Performance Based Stock Options [Member] \| Maximum [Member]
Subsequent Events (Textual)
Exercise price, Granted	$ 0.80
Exercisable sales revenue	$ 10,000,000
Subsequent Event [Member] \| Service agreements [Member]
Subsequent Events (Textual)
Number of Options, Issued	50,000
Exercise price, Granted	$ 0.20
Expire term	10 years

EXCEL 44 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 48 FilingSummary.xml IDEA: XBRL DOCUMENT 3.5.0.2 html 104 164 1 false 29 0 false 5 false false R1.htm 001 - Document - Document and Entity Information Sheet http://www.immudyne.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 002 - Statement - Consolidated Balance Sheets Sheet http://www.immudyne.com/role/Consolidatedbalancesheets Consolidated Balance Sheets Statements 2 false false R3.htm 003 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://www.immudyne.com/role/ConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 004 - Statement - Consolidated Statements of Operations (Unaudited) Sheet http://www.immudyne.com/role/ConsolidatedStatementsOfOperationsUnaudited Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 005 - Statement - Consolidated Statement of Stockholders' Equity (Unaudited) Sheet http://www.immudyne.com/role/ConsolidatedStatementOfStockholdersEquityUnaudited Consolidated Statement of Stockholders' Equity (Unaudited) Statements 5 false false R6.htm 006 - Statement - Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.immudyne.com/role/ConsolidatedStatementsOfCashFlowsUnaudited Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 007 - Disclosure - Organization and Going Concern Sheet http://www.immudyne.com/role/OrganizationAndGoingConcern Organization and Going Concern Notes 7 false false R8.htm 008 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.immudyne.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 8 false false R9.htm 009 - Disclosure - Notes Payable Notes http://www.immudyne.com/role/NotesPayable Notes Payable Notes 9 false false R10.htm 010 - Disclosure - Income Taxes Sheet http://www.immudyne.com/role/IncomeTaxes Income Taxes Notes 10 false false R11.htm 011 - Disclosure - Stockholders' Equity Sheet http://www.immudyne.com/role/StockholdersEquity Stockholders' Equity Notes 11 false false R12.htm 012 - Disclosure - Royalties Sheet http://www.immudyne.com/role/Royalties Royalties Notes 12 false false R13.htm 013 - Disclosure - Commitments and Contingencies Sheet http://www.immudyne.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 13 false false R14.htm 014 - Disclosure - Related Party Transactions Sheet http://www.immudyne.com/role/RelatedPartyTransactions Related Party Transactions Notes 14 false false R15.htm 015 - Disclosure - Subsequent Events Sheet http://www.immudyne.com/role/SubsequentEvents Subsequent Events Notes 15 false false R16.htm 016 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.immudyne.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.immudyne.com/role/SummaryOfSignificantAccountingPolicies 16 false false R17.htm 017 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.immudyne.com/role/SummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://www.immudyne.com/role/SummaryOfSignificantAccountingPolicies 17 false false R18.htm 018 - Disclosure - Income Taxes (Tables) Sheet http://www.immudyne.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://www.immudyne.com/role/IncomeTaxes 18 false false R19.htm 019 - Disclosure - Stockholders' Equity (Tables) Sheet http://www.immudyne.com/role/StockholdersEquityTables Stockholders' Equity (Tables) Tables http://www.immudyne.com/role/StockholdersEquity 19 false false R20.htm 020 - Disclosure - Organization and Going Concern (Details) Sheet http://www.immudyne.com/role/OrganizationAndGoingConcernDetails Organization and Going Concern (Details) Details http://www.immudyne.com/role/OrganizationAndGoingConcern 20 false false R21.htm 021 - Disclosure - Summary of Significant Accounting Policies (Details) Sheet http://www.immudyne.com/role/SummaryOfSignificantAccountingPoliciesDetails Summary of Significant Accounting Policies (Details) Details http://www.immudyne.com/role/SummaryOfSignificantAccountingPoliciesTables 21 false false R22.htm 022 - Disclosure - Summary of Significant Accounting Policies (Details 1) Sheet http://www.immudyne.com/role/SummaryOfSignificantAccountingPoliciesDetails1 Summary of Significant Accounting Policies (Details 1) Details http://www.immudyne.com/role/SummaryOfSignificantAccountingPoliciesTables 22 false false R23.htm 023 - Disclosure - Summary of Significant Accounting Policies (Details Textual) Sheet http://www.immudyne.com/role/Summaryofsignificantaccountingpoliciesdetailstextual Summary of Significant Accounting Policies (Details Textual) Details http://www.immudyne.com/role/SummaryOfSignificantAccountingPoliciesTables 23 false false R24.htm 024 - Disclosure - Notes Payable (Details) Notes http://www.immudyne.com/role/NotesPayableDetails Notes Payable (Details) Details http://www.immudyne.com/role/NotesPayable 24 false false R25.htm 025 - Disclosure - Income Taxes (Details) Sheet http://www.immudyne.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://www.immudyne.com/role/IncomeTaxesTables 25 false false R26.htm 026 - Disclosure - Income Taxes (Details Textual) Sheet http://www.immudyne.com/role/IncomeTaxesDetailsTextual Income Taxes (Details Textual) Details http://www.immudyne.com/role/IncomeTaxesTables 26 false false R27.htm 027 - Disclosure - Stockholders' Equity (Details) Sheet http://www.immudyne.com/role/StockholdersEquityDetails Stockholders' Equity (Details) Details http://www.immudyne.com/role/StockholdersEquityTables 27 false false R28.htm 028 - Disclosure - Stockholders' Equity (Details 1) Sheet http://www.immudyne.com/role/StockholdersEquityDetails1 Stockholders' Equity (Details 1) Details http://www.immudyne.com/role/StockholdersEquityTables 28 false false R29.htm 029 - Disclosure - Stockholders' Equity (Details 2) Sheet http://www.immudyne.com/role/StockholdersEquityDetails2 Stockholders' Equity (Details 2) Details http://www.immudyne.com/role/StockholdersEquityTables 29 false false R30.htm 030 - Disclosure - Stockholders' Equity (Details Textual) Sheet http://www.immudyne.com/role/StockholdersEquityDetailsTextual Stockholders' Equity (Details Textual) Details http://www.immudyne.com/role/StockholdersEquityTables 30 false false R31.htm 031 - Disclosure - Royalties (Details) Sheet http://www.immudyne.com/role/RoyaltiesDetails Royalties (Details) Details http://www.immudyne.com/role/Royalties 31 false false R32.htm 032 - Disclosure - Commitments and Contingencies (Details) Sheet http://www.immudyne.com/role/CommitmentsAndContingenciesDetails Commitments and Contingencies (Details) Details http://www.immudyne.com/role/CommitmentsAndContingencies 32 false false R33.htm 033 - Disclosure - Related Party Transactions (Details) Sheet http://www.immudyne.com/role/RelatedPartyTransactionsDetails Related Party Transactions (Details) Details http://www.immudyne.com/role/RelatedPartyTransactions 33 false false R34.htm 034 - Disclosure - Subsequent Events (Details) Sheet http://www.immudyne.com/role/SubsequentEventsDetails Subsequent Events (Details) Details http://www.immudyne.com/role/SubsequentEvents 34 false false All Reports Book All Reports immd-20160630.xml immd-20160630.xsd immd-20160630_cal.xml immd-20160630_def.xml immd-20160630_lab.xml immd-20160630_pre.xml true true ZIP 50 0001213900-16-016025-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-16-016025-xbrl.zip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end